var title_f23_56_24448="Cutaneous sensory distribution of the ulnar nerve";
var content_f23_56_24448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Cutaneous sensory distribution of the ulnar nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration show the cutaneous sensory distribution of the three major branches of the ulnar nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24448=[""].join("\n");
var outline_f23_56_24448=null;
var title_f23_56_24449="Retinal hamartoma";
var content_f23_56_24449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal hamartoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smaller, multinodular, calcified astrocytic hamartoma of the retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore, Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24449=[""].join("\n");
var outline_f23_56_24449=null;
var title_f23_56_24450="Patient information: Can foods or supplements lower cholesterol? (The Basics)";
var content_f23_56_24450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/38/40546\">",
"         Patient information: Vitamin supplements (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28642\">",
"         Patient information: Diet and health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/6/43108\">",
"         Patient information: High cholesterol treatment options (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9995227\">",
"      <span class=\"h1\">",
"       Can I lower my cholesterol by changing my diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you can lower your cholesterol some if you avoid red meat, butter, fried foods, cheese, and other foods that have a lot of saturated fat. But if you are interested in improving your health, it&rsquo;s best not to focus just on cholesterol. There are changes you can make to your diet that will reduce your risk of heart disease and other problems&mdash;even if they don&rsquo;t lower your cholesterol much.",
"     </p>",
"     <p>",
"      No single diet is right for everyone. But in general, a healthy diet can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lots of fruits, vegetables, and whole grains (examples of whole grains include whole wheat, oats, and barley)",
"       </li>",
"       <li>",
"        Some beans, peas, lentils, chickpeas, and similar foods",
"       </li>",
"       <li>",
"        Some nuts, such as walnuts, almonds, and peanuts",
"       </li>",
"       <li>",
"        Fat-free or low-fat milk and milk products",
"       </li>",
"       <li>",
"        Some fish",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To have a healthy diet, it&rsquo;s also important to limit or avoid sugar, sweets, and refined grains. (Refined grains are found in white bread, white rice, most forms of pasta, and most packaged &ldquo;snack&rdquo; foods.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9995242\">",
"      <span class=\"h1\">",
"       What about eggs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Eggs are OK, but don&rsquo;t overdo it. The news is often littered with stories about the health benefits or risks of eggs. The truth is, eggs are a good source of protein and do not raise cholesterol much, even though they have a lot of cholesterol in them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9995257\">",
"      <span class=\"h1\">",
"       Are there specific foods that can lower my cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. There are some foods that seem to lower cholesterol, but scientists are still not sure. Here are some foods that are being studied:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Foods rich in omega 3 fatty acids",
"        </strong>",
"        &ndash; Foods rich in omega 3 fatty acids include oily fish, and olive and canola oil. These foods seem to raise good cholesterol and might lower certain types of bad cholesterol. More important, studies show that people who eat lots of these foods are less likely than those who eat less of them to have heart disease. If you want, it&rsquo;s fine to eat 1 to 2 servings of oily fish a week (such as salmon, herring, or tuna). If you would like to take fish oil supplements, talk to your doctor or nurse.",
"       </li>",
"       <li>",
"        <strong>",
"         Nuts &ndash;",
"        </strong>",
"        Some studies show that eating certain nuts, such as walnuts and pistachios, can help lower cholesterol and even the risk of heart attack or death.",
"       </li>",
"       <li>",
"        <strong>",
"         Fiber-rich foods",
"        </strong>",
"        &ndash; Fiber-rich foods, such as fruits, vegetables, beans, and oats, seem to lower cholesterol and are generally good for your health. Some doctors even recommend fiber supplements.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9995272\">",
"      <span class=\"h1\">",
"       What about designer foods that claim to lower cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Be careful with these foods. There are now many foods that have added plant extracts called &ldquo;sterols&rdquo; or &ldquo;stanols.&rdquo; Examples include Minute Maid HeartWise orange juice, Danacol yogurt, and special margarines such as Benecol and Promise activ. Foods with added sterols or stanols can lower cholesterol. But it&rsquo;s not clear whether those foods help reduce the risk of heart attack or stroke. Plus, research in animals shows that these extracts might actually cause health problems. Experts think more research is needed before they can recommend that people eat foods with added plant sterols or stanols.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9995289\">",
"      <span class=\"h1\">",
"       Should I take supplements to lower my cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Some research has shown that certain supplements can lower cholesterol. But there is almost no research showing that supplements can help prevent heart attacks, strokes, or any of the problems caused by high cholesterol. If you decide to try supplements, keep in mind that in the United States, the government does not regulate supplements very well. That means that what&rsquo;s on a supplement&rsquo;s label is not always actually in the bottle.",
"     </p>",
"     <p>",
"      Here are some supplements that might help with cholesterol:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Red yeast rice",
"        </strong>",
"        &ndash; This supplement can contain the same ingredient that is in a prescription medicine to lower cholesterol. Red yeast rice helps lower cholesterol, but the products that claim to have it might not always have much of the active ingredient.",
"       </li>",
"       <li>",
"        <strong>",
"         Calcium",
"        </strong>",
"        &ndash; Some studies show that calcium supplements can lower cholesterol. But there are no studies showing that they lower the risk of heart attack or stroke. Some studies even suggest that calcium supplements can increase these risks.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9995304\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"       Patient information: Vitamin supplements (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       Patient information: Diet and health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       Patient information: High cholesterol treatment options (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/56/24450?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87108 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24450=[""].join("\n");
var outline_f23_56_24450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9995227\">",
"      Can I lower my cholesterol by changing my diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9995242\">",
"      What about eggs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9995257\">",
"      Are there specific foods that can lower my cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9995272\">",
"      What about designer foods that claim to lower cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9995289\">",
"      Should I take supplements to lower my cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9995304\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=related_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24451="Diflorasone: Drug information";
var content_f23_56_24451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diflorasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/8/43139?source=see_link\">",
"    see \"Diflorasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ApexiCon&reg; E;",
"     </li>",
"     <li>",
"      ApexiCon&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroid-responsive dermatosis: Topical: Apply ointment sparingly 1-3 times/day; apply cream sparingly 2-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as diacetate: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ApexiCon&reg; E: 0.05% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as diacetate: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ApexiCon&trade;: 0.05% (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relieves inflammation and pruritic symptoms of corticosteroid-responsive dermatosis (high to very high potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11347524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Florone [Germany, Greece] may be confused with Flogene brand name for piroxicam [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Arthralgia, burning, dryness, folliculitis, itching, maceration, muscle atrophy, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diflorasone",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animals administered potent topical corticosteroids. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13277392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13277391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if topical application will result in detectable quantities in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (ApexiCon E External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $357.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Diflorasone Diacetate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $169.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (ApexiCon External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $117.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Diflorasone Diacetate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $51.86",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diflorate (IN);",
"     </li>",
"     <li>",
"      Florone (DE, GR);",
"     </li>",
"     <li>",
"      Taesun Cream (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Negligible, around 1% reaches dermal layers or systemic circulation; occlusive dressings increase absorption percutaneously",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/56/24451/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9356 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24451=[""].join("\n");
var outline_f23_56_24451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159921\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159930\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159923\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159924\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159910\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159897\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159911\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347524\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159929\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159915\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159901\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299193\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159906\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159907\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277390\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277392\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277391\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159916\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159917\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159900\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159914\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/8/43139?source=related_link\">",
"      Diflorasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24452="Atlas of thyroid cytopathology";
var content_f23_56_24452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atlas of thyroid cytopathology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24452/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24452/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24452/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24452/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24452/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24452/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/56/24452/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration (FNA) biopsy and fine needle capillary sampling are the two most widely used diagnostic techniques for assessing the cytopathology of thyroid nodules to identify those patients who have nodules that should be excised. This topic will review the most common cytopathologic findings and the clinical entities they represent. Thyroid biopsy techniques (including core needle biopsies) and their indications, utility, and complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=see_link\">",
"     \"Ultrasound-guided thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928059\">",
"    <span class=\"h1\">",
"     FOLLICULAR LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytologic diagnosis of follicular lesion includes cells with a macrofollicular (abundant colloid, fragments of macrofollicles forming flat sheets of uniform follicular cells), microfollicular (scant colloid, small microfollicles or &ldquo;rosettes&rdquo; of crowded cells), or mixed (macrofollicles and microfollicles, or cells with mild nuclear atypia, or extensive oncocytic change) pattern (",
"    <a class=\"graphic graphic_table graphicRef70424 \" href=\"UTD.htm?4/60/5068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Benign (macrofollicular) cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;This pattern may also be referred to as adenomatoid, hyperplastic, or colloid adenomas. Large colloid-filled thyroid follicles are found in normal thyroid tissue, sporadic goiter, and monoclonal macrofollicular tumors.",
"   </p>",
"   <p>",
"    Surgical specimens of sporadic goiter often contain many such macrofollicles (",
"    <a class=\"graphic graphic_picture graphicRef71842 \" href=\"UTD.htm?14/21/14674\">",
"     picture 1",
"    </a>",
"    ). During needle aspiration, the follicles are frequently disrupted so that the colloid is smeared across the slide, or occasionally is aggregated into droplets. The follicular cells lining the follicles may remain intact, or break apart and form sheets.",
"   </p>",
"   <p>",
"    Cytology of macrofollicular nodules may show both intact macrofollicles and macrofollicles that have been broken apart forming a flat sheet (",
"    <a class=\"graphic graphic_picture graphicRef76239 \" href=\"UTD.htm?16/15/16628\">",
"     picture 2",
"    </a>",
"    ). The cells appear uniform in size and are not crowded together. Follicle size may vary, with a few microfollicles interspersed among the macrofollicles, especially if the sample was obtained from an area close to the capsule of the lesion. At high power the follicular cells are seen to be small, uniform in size, flat, and non-crowded, and smeared colloid is seen in the background (",
"    <a class=\"graphic graphic_picture graphicRef64419 \" href=\"UTD.htm?37/35/38450\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Macrofollicular nodules may have areas of cystic degeneration with cellular debris and hemosiderin-laden macrophages. There may be focal H&uuml;rthle (oxyphil) cell change and rarely multinucleated giant cells (see below).",
"   </p>",
"   <p>",
"    Colloid, which stains blue on a Papanicolaou stain, is usually abundant in the background of macrofollicular lesions (",
"    <a class=\"graphic graphic_picture graphicRef52463 \" href=\"UTD.htm?1/39/1649\">",
"     picture 4",
"    </a>",
"    ). Colloid may also be obtained from colloid cysts, and those smears may have few or no intact follicular cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Follicular neoplasm/microfollicular cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;This pattern may also be referred to as cellular or indeterminate. Microfollicular cytology may be seen in aspirates from follicular adenomas, follicular carcinomas, follicular variant of papillary cancer, and occasionally from autonomously functioning thyroid nodules.",
"   </p>",
"   <p>",
"    Microfollicles are easily identified in specimens obtained by FNA (",
"    <a class=\"graphic graphic_picture graphicRef74281 \" href=\"UTD.htm?14/40/14980\">",
"     picture 5",
"    </a>",
"    ). Colloid is absent or scant, and the cells are more crowded than in macrofollicular nodules and may form clusters. Well-developed microfollicles, crowding, and scant colloid is the least worrisome pattern. More suspicious is the absence of follicle formation, cells arranged in clusters and clumps, and varying nuclear atypia and cellular pleomorphism (",
"    <a class=\"graphic graphic_picture graphicRef54002 \" href=\"UTD.htm?13/55/14196\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since fine needle aspiration samples only a portion of the nodule, surgical excision and extensive sectioning are required to determine if a microfollicular lesion is benign or malignant. Microfollicular nodules which do not show vascular or capsular invasion after surgical excision are considered benign, while those that demonstrate even focal microscopic invasion are classified as follicular carcinomas. Surgically excised microfollicular adenomas show well-developed microfollicles with considerably less colloid than is seen in macrofollicular nodules (",
"    <a class=\"graphic graphic_picture graphicRef61481 \" href=\"UTD.htm?16/24/16777\">",
"     picture 7",
"    </a>",
"    ). This pattern of well-developed microfollicles was previously referred to as a \"fetal adenoma,&rdquo; as it is reminiscent histologically of the fetal thyroid. However, if invasion is seen, then as noted above the pathologic diagnosis is follicular cancer. Lesions with less definite or no follicle formation, called cellular or trabecular adenomas (previously referred to as \"embryonal adenomas\"), are more likely to show vascular or capsule invasion.",
"   </p>",
"   <p>",
"    Autonomously functioning thyroid nodules (which are virtually always benign) may appear to be suspicious for a follicular neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24452/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3109040\">",
"    <span class=\"h2\">",
"     Follicular lesion of undetermined significance (FLUS) or atypia of undetermined significance (AUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This designation is used when there are cells with mild nuclear atypia (AUS), when the lesion has approximately equal number of macrofollicular fragments and microfollicles (FLUS), or when there is extensive oncocytic (H&uuml;rthle cell) change, but not enough to be classified as H&uuml;rthle cell neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24452/abstract/2\">",
"     2",
"    </a>",
"    ]. This designation is also used for specimens that are compromised because of poor fixation or obscuring blood.",
"   </p>",
"   <p>",
"    Nodules with features of both macrofollicular fragments and microfollicular lesions are common, especially in nodular goiters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     H&uuml;rthle cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;H&uuml;rthle cells (also called oncocytes or Askanazy or oxyphil cells) are large polyclonal cells with abundant oxyphil cytoplasm. Sheets of H&uuml;rthle cells are seen in H&uuml;rthle-cell adenomas (",
"    <a class=\"graphic graphic_picture graphicRef60286 \" href=\"UTD.htm?17/3/17458\">",
"     picture 8",
"    </a>",
"    ). Analogous to microfollicular adenomas, H&uuml;rthle-cell adenomas are benign if there is no evidence of vascular or capsular invasion on pathologic examination of the excised nodule, and malignant (H&uuml;rthle-cell cancer or follicular cancer, oxyphil cell type) if invasion is present.",
"   </p>",
"   <p>",
"    Focal H&uuml;rthle-cell change can be seen in both degenerating macrofollicular lesions and Hashimoto's thyroiditis. Because of limited sampling, scant FNA specimens from these disorders may show apparent sheets of H&uuml;rthle cells and can result in a false positive cytologic diagnosis of a H&uuml;rthle-cell tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HASHIMOTO'S THYROIDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable histologic variability in both FNA and histologic specimens from Hashimoto's thyroiditis. In surgical specimens, some sections are composed of normal appearing follicles with minimal lymphocytic infiltration, while other areas show complete destruction of follicles with dense lymphocytic infiltration and lymphoid germinal centers (",
"    <a class=\"graphic graphic_picture graphicRef57542 \" href=\"UTD.htm?36/18/37158\">",
"     picture 9",
"    </a>",
"    ). Plasma cells are commonly seen, as are H&uuml;rthle-cell changes in the remaining follicular cells, and fibrosis may be prominent.",
"   </p>",
"   <p>",
"    Each of these findings may be the major cytologic feature in fine needle aspirates. In some patients the aspirates consist mostly of lymphocytes surrounding rare follicular cells (",
"    <a class=\"graphic graphic_picture graphicRef74981 \" href=\"UTD.htm?11/46/12001\">",
"     picture 10",
"    </a>",
"    ). Since blood lymphocytes contaminate most FNA specimens, the diagnosis of thyroiditis can be challenging. However, lymphocytes embedded within tissue are more fragile and tear easily when smeared (",
"    <a class=\"graphic graphic_picture graphicRef54693 \" href=\"UTD.htm?7/40/7813\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some aspirates are devoid of any follicular cells and may be read as nondiagnostic. Nevertheless, a presumptive diagnosis of Hashimoto's thyroiditis can be made if other cytologic features are present, such as lymphocytes, plasma cells, germinal centers and fibrotic follicles, and if the clinical presentation is compatible with this disorder. Another potential problem is that the H&uuml;rthle (oxyphil) cell changes may result in a false positive interpretation of a H&uuml;rthle-cell tumor. In addition, it may be necessary to do flow cytometry when cytology specimens show only lymphocytes to exclude the possibility of a well-differentiated lymphoma.",
"   </p>",
"   <p>",
"    Since the diagnosis of Hashimoto's thyroiditis can be made in most patients on the basis of the clinical presentation and laboratory findings, FNA should not be performed unless a discrete nodule is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PAPILLARY CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with papillary cancer, the surgical specimen typically shows a papillary structure, with or without follicles, and little or no colloid (",
"    <a class=\"graphic graphic_picture graphicRef81310 \" href=\"UTD.htm?1/17/1305\">",
"     picture 12",
"    </a>",
"    ). In occasional cases, only follicular development is seen. The diagnosis of papillary cancer then is based upon the cytologic features of the cells; these tumors are called the follicular variant of papillary cancer.",
"   </p>",
"   <p>",
"    Papillary carcinomas have distinct cytologic features that can be seen in high power views of fine needle aspirates. The cells and nuclei are large, and their cytoplasm has a \"ground glass\" appearance. The nuclei have clefts, grooves, and \"holes\" due to intranuclear cytoplasmic inclusions (\"Orphan Annie eyes\"), and the nucleoli are small (",
"    <a class=\"graphic graphic_picture graphicRef71385 \" href=\"UTD.htm?11/21/11603\">",
"     picture 13",
"    </a>",
"    ). Other features include psammoma bodies, sticky or &ldquo;bubblegum&rdquo; colloid, and occasional epithelioid giant cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psammoma bodies are small laminated calcifications that are frequently seen in papillary carcinomas, but can rarely occur in benign thyroid lesions (",
"      <a class=\"graphic graphic_picture graphicRef72821 \" href=\"UTD.htm?4/59/5042\">",
"       picture 14",
"      </a>",
"      ). The laminations can best be seen under the microscope by moving the depth of focus.",
"     </li>",
"     <li>",
"      Sticky colloid is seen in papillary carcinomas. Although colloid is scant in this disorder, the colloid that is present appears to \"stick\" to debris and cell clusters, instead of smearing across the slide (",
"      <a class=\"graphic graphic_picture graphicRef57514 \" href=\"UTD.htm?26/54/27492\">",
"       picture 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Epithelioid giant cells can be seen in papillary carcinomas, but are also frequently seen in degenerating areas of macrofollicular nodules and in subacute granulomatous thyroiditis (",
"      <a class=\"graphic graphic_picture graphicRef67770 \" href=\"UTD.htm?31/3/31792\">",
"       picture 16",
"      </a>",
"      ). However, patients with the latter disorder rarely undergo FNA because the clinical manifestations of subacute granulomatous thyroiditis are so characteristic that FNA is rarely indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=see_link\">",
"       \"Subacute thyroiditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MEDULLARY CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical specimens from patients with medullary cancer of the thyroid show spindle-shaped and frequently pleomorphic cells without follicle development because these cells originate from the calcitonin-producing parafollicular C-cells of the thyroid (",
"    <a class=\"graphic graphic_picture graphicRef82093 \" href=\"UTD.htm?36/9/37013\">",
"     picture 17",
"    </a>",
"    ). Occasional red cytoplasmic granules are seen, and the supporting stroma frequently stains for amyloid.",
"   </p>",
"   <p>",
"    Identification of medullary cancer in FNA specimens can be difficult because the cells tend to disperse on the slide. Their nuclei are placed eccentrically, and they are larger and more pleomorphic than those of normal follicular cells. The cytoplasm may be slightly granular, and is usually configured as a tear drop or cytoplasmic tail. If the diagnosis is suspected, immunocytologic staining for calcitonin should be performed (",
"    <a class=\"graphic graphic_picture graphicRef56242 \" href=\"UTD.htm?30/6/30831\">",
"     picture 18",
"    </a>",
"    ). The cellular pleomorphism and lack of follicular development usually results in a recommendation for surgical excision even if the diagnosis is not made on FNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    The clinical importance of thyroid nodules is primarily related to the need to exclude thyroid cancer, which is present in 4 to 6.5 percent of thyroid nodules. If a serum TSH is normal, the next step in the evaluation of a thyroid nodule is a fine needle aspiration biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common cytopathologic findings and the clinical entities they represent are described above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign (macrofollicular) cytology (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Benign (macrofollicular) cytology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Microfollicular cytology (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Follicular neoplasm/microfollicular cytology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hashimoto's thyroiditis (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Hashimoto's thyroiditis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Papillary cancer (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Papillary cancer'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Medullary cancer (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Medullary cancer'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thyroid biopsy techniques (including core needle biopsies) and their indications, utility, and complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of thyroid nodules is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24452/abstract/1\">",
"      Walfish PG, Strawbridge HT, Rosen IB. Management implications from routine needle biopsy of hyperfunctioning thyroid nodules. Surgery 1985; 98:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24452/abstract/2\">",
"      Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009; 19:1159.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7823 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24452=[""].join("\n");
var outline_f23_56_24452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1928059\">",
"      FOLLICULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Benign (macrofollicular) cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Follicular neoplasm/microfollicular cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3109040\">",
"      Follicular lesion of undetermined significance (FLUS) or atypia of undetermined significance (AUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      H&uuml;rthle cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HASHIMOTO'S THYROIDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PAPILLARY CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MEDULLARY CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7823|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/21/14674\" title=\"picture 1\">",
"      Thyroid goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/15/16628\" title=\"picture 2\">",
"      Benign macrofollicular thyroid lesion low power view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/35/38450\" title=\"picture 3\">",
"      Benign macrofollicular thyroid lesion high power view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/39/1649\" title=\"picture 4\">",
"      Thyroid colloid FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/40/14980\" title=\"picture 5\">",
"      Microfollicular adenoma FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/55/14196\" title=\"picture 6\">",
"      Follicular carcinoma FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/24/16777\" title=\"picture 7\">",
"      Benign microfollicular adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/3/17458\" title=\"picture 8\">",
"      Hurthle cell lesion FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/18/37158\" title=\"picture 9\">",
"      Hashimotos thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/46/12001\" title=\"picture 10\">",
"      Hashimotos thyroiditis FNA I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/40/7813\" title=\"picture 11\">",
"      Hashimotos thyroiditis FNA II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/17/1305\" title=\"picture 12\">",
"      Papillary carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/21/11603\" title=\"picture 13\">",
"      Papillary thyroid cancer FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/59/5042\" title=\"picture 14\">",
"      Psammoma body FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/54/27492\" title=\"picture 15\">",
"      Sticky colloid FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/3/31792\" title=\"picture 16\">",
"      Epithelioid giant cell FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/9/37013\" title=\"picture 17\">",
"      Medullary thyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/6/30831\" title=\"picture 18\">",
"      Medullary thyroid carcinoma FNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/60/5068\" title=\"table 1\">",
"      Cytology of follicular thyroid lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=related_link\">",
"      Subacute thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=related_link\">",
"      Thyroid biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=related_link\">",
"      Ultrasound-guided thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24453="Statin therapy in patients with heart failure";
var content_f23_56_24453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Statin therapy in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24453/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24453/contributors\">",
"     Prakash C Deedwania, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24453/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24453/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24453/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24453/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/56/24453/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy is widely used for both the secondary and primary prevention of atherosclerotic cardiovascular disease. However, the randomized trials that have provided evidence of benefit have included few patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, two major randomized trials, CORONA and GISSI-HF, have directly addressed this issue in patients with systolic HF. In addition, HF management is potentially complicated by the observation that low serum cholesterol is associated with worse outcomes.",
"   </p>",
"   <p>",
"    These issues will be reviewed here. The role of statin therapy in the broad group of patients with cardiovascular disease and the multiple mechanisms by which statins might act in addition to cholesterol lowering are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SERUM CHOLESTEROL AND PROGNOSIS IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low serum cholesterol in patients with HF is associated with higher mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. The following observations illustrated the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 1134 patients with advanced, chronic HF (almost all New York Heart Association [NYHA] class III or IV) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ), mean left ventricular ejection fraction [LVEF] 22 percent), the serum cholesterol was higher in survivors compared to nonsurvivors at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients in the lowest quintile of serum cholesterol (&lt;129",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.3",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      had an adjusted relative mortality risk of 2.1 compared to those in the highest quintile (serum cholesterol &gt;223",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.8",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"      Low cholesterol appeared to be a marker for more severe disease, since these patients also had other findings known to predict worse outcomes in patients with HF, including lower serum albumin, lower serum sodium, and lower LVEF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"       \"Predictors of survival in heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"       \"Prognosis of heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A relationship between lower serum cholesterol levels (less than 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.2",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      and higher mortality was also found in a multivariable analysis of 114 patients with chronic HF [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/4\">",
"       4",
"      </a>",
"      ]. The multivariable model was validated in a second group of 303 additional patients with HF. The findings were independent of the etiology of HF.",
"     </li>",
"     <li>",
"      A similar relationship between lower serum cholesterol levels and higher mortality was also found in a multivariable analysis of almost 18,000 patients presenting with short-term (acute) heart failure exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether low cholesterol has a causative role or is simply a marker of more severe debilitation (ie, cardiac cachexia, liver dysfunction, and inadequate nutrition), has not been determined. Thus, there is a theoretical concern that lipid lowering with statins may have an adverse effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL BENEFITS AND HARMS OF STATIN THERAPY IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins have a variety of lipid-independent (pleiotropic) effects that could contribute to improved outcomes in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiatherogenic and plaque-stabilizing properties and improvement in endothelial function, which together reduce the risk of an acute coronary syndrome and the ischemic burden on the failing ventricle. However, the rates of myocardial infarction are low in patients with HF, making it more difficult to demonstrate benefit from statin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of proinflammatory cytokine activity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/8\">",
"       8",
"      </a>",
"      ], favorable modulation of the autonomic nervous system, and an antiarrhythmic effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are at least two mechanisms by which statin use might be harmful in patients with HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipoproteins may remove bacterial endotoxins (lipopolysaccharides) that enter the circulation. By lowering lipoprotein levels, statins might make HF patients more susceptible to infection [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasma levels of ubiquinone (coenzyme Q10) are reduced during treatment with statins. Ubiquinone is a coenzyme in mitochondrial respiration, and depletion might adversely affect cardiac muscle. Serum ubiquinone levels have been inversely related to mortality in patients with HF [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STATINS IN SYSTOLIC HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early evidence of the role of statins in patients with systolic HF came from observational studies and post hoc subgroup analyses in statin trials for coronary disease. which tended to support benefit from statin use [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/6,11-14\">",
"     6,11-14",
"    </a>",
"    ]. In addition, two small randomized trials that evaluated surrogate endpoints came to differing conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data on the role of statin therapy in patients with systolic HF comes from two large randomized trials published in 2007 and 2008 (CORONA and GISSI-HF), neither of which showed benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     CORONA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the CORONA trial, 5011 patients (mean age 73 years) with NYHA class II to IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) ischemic systolic HF (mean LVEF 31 percent) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    10 mg daily or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/16\">",
"     16",
"    </a>",
"    ]. At baseline, the mean serum LDL-cholesterol concentration was 137",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.55",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    An entry requirement was that the investigator thought that the patient did not need a cholesterol lowering drug.",
"   </p>",
"   <p>",
"    The following findings were noted at a median follow-up of 33 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      reduced LDL levels (76 versus 138",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.96 versus 3.57",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      and also had beneficial effects on HDL-C and triglycerides.",
"     </li>",
"     <li>",
"      Despite these biochemical changes, there was no significant reduction in the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (11.4 versus 12.3 percent with placebo, hazard ratio [HR] 0.92, 95% CI 0.83-1.02), or secondary outcomes such as cardiovascular mortality (9.3 versus 9.6 percent, HR 0.97), or coronary events (9.3 versus 10.0 percent, HR 0.92).",
"     </li>",
"     <li>",
"      A post-hoc, subset analysis of the 3664 patients in whom baseline N-terminal pro B-type brain natriuretic peptide (NT-proBNP) levels were available, compared outcomes in the statin and placebo groups by tertile [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients in the lowest tertile of NT-proBNP (less than 103",
"      <span class=\"nowrap\">",
"       pmol/L",
"      </span>",
"      [868",
"      <span class=\"nowrap\">",
"       pg/mL]),",
"      </span>",
"      which is a marker for a better prognosis, had a significantly lower primary composite end point with statin therapy (HR 0.65, 95% CI 0.47-0.88). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H10#H10\">",
"       \"Natriuretic peptide measurement in heart failure\", section on 'Plasma BNP in heart failure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     GISSI-HF trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the GISSI-HF trial, 4574 patients (mean age 68 years) with ischemic or nonischemic NYHA class II to IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and a mean LVEF of 33 percent were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    10 mg daily or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/18\">",
"     18",
"    </a>",
"    ]. Serum LDL cholesterol fell from 122 to 89",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.16 to 2.31",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    after three years of rosuvastatin compared to no significant change with placebo.",
"   </p>",
"   <p>",
"    At a median follow-up of 47 months, there was no significant difference in deaths from any cause (29 versus 28 percent with placebo), or in the combined end point of death or admission to the hospital for cardiovascular causes in both ischemic (HR 1.03) and nonischemic cardiomyopathy (HR 1.02).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CORONA and GISSI-HF trials suggest that the initiation of statin therapy is not useful in patients with systolic HF with or without coronary artery disease. CORONA raised the possibility that statins might be beneficial in patients with ischemic systolic HF with NT-proBNP values in the lowest tertile [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/17\">",
"     17",
"    </a>",
"    ]. In the absence of confirmatory data, we suggest not using statin therapy in such patients.",
"   </p>",
"   <p>",
"    In addition, the following concerns have been raised with regard to whether the results can be generalized to all patients with systolic HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients enrolled had moderate to severe disease and were older [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Only one statin was tested and at a low to moderate dose [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ischemic events occur less frequently in patients with HF and systolic dysfunction than in the broad population of patients with established cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/7\">",
"       7",
"      </a>",
"      ]. As a result, it may be harder to demonstrate benefit from statin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The question of whether patients on statin therapy who develop HF benefit from continued therapy has not been addressed in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STATINS IN DIASTOLIC HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational data suggest that statins might be of benefit in patients with diastolic HF. This potential effect was illustrated in a report of 137 consecutive patients with HF and a left ventricular ejection fraction (LVEF) &ge;50 percent who did not have known coronary heart disease, significant valvular disease, or end-stage renal disease; one-half were treated with a statin at the discretion of the physician [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24453/abstract/20\">",
"     20",
"    </a>",
"    ]. The patients treated with a statin had a higher baseline LDL-cholesterol concentration than those not treated but the posttherapy values were similar in the two groups. At a mean follow-up of 21 months, statin therapy was associated with a lower mortality after adjustment for differences in baseline variables (adjusted relative risk 0.20, 95% CI 0.06-0.62). This difference observed in mortality is greater than that seen with statin therapy in other groups of patients, which calls into question whether confounding factors contribute to the difference seen.",
"   </p>",
"   <p>",
"    Randomized trials are required to confirm these observations, particularly with the apparent lack of benefit of initiating statin therapy in patients with systolic HF. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Statins in systolic HF'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite strong evidence of benefit for statins in most subsets of patients with established cardiovascular disease, two large randomized trials found no benefit from initiating statin therapy in patients with symptomatic systolic heart failure (ischemic or nonischemic) and a mean left ventricular ejection fraction &le;33 percent. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Statins in systolic HF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with more than mild HF and a left ventricular ejection fraction less than 35 percent due to either ischemic heart disease or a nonischemic cardiomyopathy, we recommend not starting statin therapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). This recommendation includes patients with a nonischemic cardiomyopathy who would have otherwise met criteria for initiation of statin therapy for the purpose of primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mild heart failure and a left ventricular ejection fraction less than 35 percent should receive statin therapy according to standard indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'CORONA trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients already on a statin for another appropriate indication at the time they develop HF, we suggest continuing statin therapy (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with diastolic HF, the decision to start statin therapy should be based upon other indications, such as the presence of atherosclerotic cardiovascular disease or LDL-cholesterol levels above guideline cutoffs.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/1\">",
"      Deedwania PC, Javed U. Statins in heart failure. Cardiol Clin 2008; 26:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/2\">",
"      Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006; 113:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/3\">",
"      Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/4\">",
"      Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/5\">",
"      Horwich TB, Hernandez AF, Dai D, et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008; 156:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/6\">",
"      Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/7\">",
"      Masoudi FA. Statins for ischemic systolic heart failure. N Engl J Med 2007; 357:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/8\">",
"      Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/9\">",
"      Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/10\">",
"      Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 2008; 52:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/11\">",
"      Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/12\">",
"      Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006; 47:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/13\">",
"      Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/14\">",
"      Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol 2007; 99:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/15\">",
"      Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/16\">",
"      Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/17\">",
"      Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/18\">",
"      Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/19\">",
"      Fonarow GC. Randomized clinical outcome trials of statins in heart failure. Heart Fail Clin 2008; 4:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24453/abstract/20\">",
"      Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112:357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1493 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24453=[""].join("\n");
var outline_f23_56_24453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SERUM CHOLESTEROL AND PROGNOSIS IN HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL BENEFITS AND HARMS OF STATIN THERAPY IN HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STATINS IN SYSTOLIC HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CORONA trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GISSI-HF trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STATINS IN DIASTOLIC HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24454="Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults";
var content_f23_56_24454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24454/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24454/contributors\">",
"     Kathe G Henke, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24454/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24454/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24454/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24454/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/56/24454/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive obstruction of the upper airway during sleep is the defining feature of obstructive sleep apnea (OSA), a disorder that is characterized by obstructive apneas and hypopneas. OSA is associated with many clinically important consequences, including excessive daytime sleepiness, impaired daytime function, metabolic dysfunction, and an increased risk of cardiovascular disease and mortality.",
"   </p>",
"   <p>",
"    The mechanisms and sites of upper airway obstruction during sleep are discussed here. The clinical manifestations, diagnosis, and treatment of OSA are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway narrowing during sleep is normal. However, when certain factors are superimposed upon those that cause normal upper airway narrowing, an abnormal degree and frequency of upper airway obstruction may result. In this section, we first review the mechanism of normal upper airway narrowing during sleep, and then describe the additional factors that lead to upper airway obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24566144\">",
"    <span class=\"h2\">",
"     Normal upper airway narrowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway luminal diameter and patency depend upon a balance of outward and inward forces. The balance favors a patent upper airway during wakefulness. However, changes occur during sleep that alter this balance and allow normal airway narrowing (",
"    <a class=\"graphic graphic_figure graphicRef58289 \" href=\"UTD.htm?27/57/28573\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The changes include a decreased neural drive to the respiratory muscles, a reduction in upper airway compensatory reflexes, and a supine sleep position:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Drive to the muscles",
"      </strong>",
"      &ndash; Decreased brainstem motor neuron activity during sleep reduces the neural drive to the upper airway dilator muscles, as well as the neural drive to the chest wall and accessory muscles of breathing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/3\">",
"       3",
"      </a>",
"      ]. When this occurs, the tonic activity of the upper airway dilator muscles is reduced, resulting in upper airway narrowing. The narrowing worsens during inspiration because contraction of the inspiratory muscles of the chest wall and accessory muscles tends to generate negative intraluminal pressure. It is widely believed that this is the primary cause of normal airway narrowing during sleep. Alcohol, benzodiazepines, and other sedative agents may contribute to upper airway narrowing during sleep by further inhibiting upper airway muscle activity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The decrease in the activity of brainstem motor neurons during sleep, particularly during rapid eye movement (REM) sleep, is probably due to diminished serotonergic signalling. This notion is supported by the observations that serotonin is excitatory to upper airway motor neurons and that serotonin antagonists suppress upper airway motor activity and increase the collapsibility of the upper airway [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The reduced drive to the respiratory muscles probably affects only tonic muscle activity, and not phasic muscle activity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Tonic activity refers to muscle activity that responds slowly to stimulation (eg, respiratory muscles during expiration). Phasic activity refers to muscle activity that responds quickly to stimulation (eg, respiratory muscles primarily during inspiration). The impact of the preferential effect on tonic activity was demonstrated by a study of the tensor palatini muscle that found that a reduction in the tonic activity was accompanied by an increase in esophageal pressure and a reduction in flow, which indicate an increase in inspiratory resistance (",
"      <a class=\"graphic graphic_figure graphicRef67836 \" href=\"UTD.htm?39/59/40892\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/9\">",
"       9",
"      </a>",
"      ]. Phasic activity appears to be unchanged (or may even increase during non-rapid eye movement sleep) because it is maintained by noradrenergic mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/7,10\">",
"       7,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Compensatory reflexes",
"      </strong>",
"      &ndash; Upper airway dilator muscle activity (eg, genioglossus) normally increases during wakefulness to compensate for the forces that promote upper airway narrowing. This was illustrated by a study that found that patients with OSA have higher upper airway muscle activity than non-snorers during wakefulness, presumably to compensate for the smaller airway of patients with OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/11\">",
"       11",
"      </a>",
"      ]. Sleep can reduce, eliminate,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delay the genioglossus' compensatory dilating response, resulting in upper airway narrowing at sleep onset [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Sleep position",
"      </strong>",
"      &ndash; Body position during sleep may play an important role in normal upper airway narrowing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/14\">",
"       14",
"      </a>",
"      ]. Soft tissues (eg, tongue, soft palate) can be drawn into the pharyngeal airway by the effects of gravity when an individual is supine, narrowing the upper airway behind the tongue and soft palate (",
"      <a class=\"graphic graphic_figure graphicRef67736 \" href=\"UTD.htm?41/25/42396\">",
"       figure 3",
"      </a>",
"      ). In addition, the horizontal sleep posture decreases lung volume, which has been shown to cause upper airway narrowing, possibly by reducing caudal traction on the airway [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/1,15\">",
"       1,15",
"      </a>",
"      ]. Upper airway narrowing has not been reported in patients with reduced lung volumes due to intrinsic lung disease, possibly because intrinsic lung disease has a different effect on diaphragm position and pleural pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/16\">",
"       16",
"      </a>",
"      ]. Finally, it has been proposed that fluid shifts from the lower to the upper body during recumbency may predispose the patient to upper airway obstruction during sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper airway narrows during sleep in all individuals, as described above. However, when certain factors are superimposed upon the factors that cause normal upper airway narrowing, upper airway obstruction may result. Upper airway obstruction causes the obstructive apneas and hypopneas that define obstructive sleep apnea (OSA). The superimposed factors can be categorized as either anatomic or neural.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Anatomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any anatomic abnormality that causes focal upper airway narrowing can contribute to airway obstruction during sleep. The increased resistance caused by the narrowing creates a pressure gradient across the narrowed site and the low pressure portion of the upper airway is then at increased risk for obstruction when the muscle tone is reduced during sleep.",
"   </p>",
"   <p>",
"    Thickened lateral pharyngeal walls account for the upper airway narrowing in most individuals with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/19\">",
"     19",
"    </a>",
"    ]. However, other sources of upper airway narrowing in patients with OSA include nasal congestion, physical obstruction (eg, tonsillar hypertrophy) (",
"    <a class=\"graphic graphic_picture graphicRef80324 \" href=\"UTD.htm?38/17/39199\">",
"     picture 1",
"    </a>",
"    ), macroglossia, facial malformations (bony and soft tissue), and various genetic factors that affect upper airway size and tissue volume [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/20\">",
"     20",
"    </a>",
"    ]. Obesity contributes to the upper airway narrowing in several ways, including fatty infiltration of the areas surrounding the airway, the tongue, and the fat pads lateral to the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/21\">",
"     21",
"    </a>",
"    ]. The airway&rsquo;s shape and transmural pressure (increased by obesity) are also important contributors to the collapsibility of the upper airway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neural factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of upper airway patency depends upon appropriate activity and timing of upper airway muscles during inspiration. The upper airway dilator muscles must be sufficiently active to hold the airway open against the suction forces created by the inspiratory muscles and they must be activated before the inspiratory forces are generated or patency of the upper airway will be compromised. Activation of the inspiratory muscles prior to genioglossus activation has been shown to cause complete or partial upper airway obstruction, leading to apneic, hypopneic, or high resistance breaths (",
"    <a class=\"graphic graphic_figure graphicRef66734 \" href=\"UTD.htm?28/31/29182\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/23\">",
"     23",
"    </a>",
"    ]. These abnormal breaths may lead to arousals from sleep, causing sleep disruption. Sleep disruption may reduce upper airway muscle activation, thereby establishing a vicious cycle in which sleep disruption leads to worsening of the sleep-related breathing disorder, which then leads to further sleep disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other neural factors may also contribute to upper airway obstruction, but these are less well studied. Emerging evidence suggests that leptin resistance that is associated with increased visceral fat may play a role in respiratory depression and subsequent upper airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, repeated trauma to the mucosa and tissue of the upper airway has been shown to cause cellular inflammation and neuropathy, which may affect the contractibility of the upper airway dilator muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced upper airway sensitivity was proposed as a contributor to OSA, but studies failed to show that a reduction in upper airway sensitivity correlated with the severity of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. A possible exception is the subpopulation of patients for whom velopharyngeal insensitivity correlates with OSA severity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/27\">",
"     27",
"    </a>",
"    ], although it remains unclear if velopharyngeal insensitivity is a consequence of the severity of OSA, or if the severity of OSA is a consequence of the velopharyngeal insensitivity Upper airway muscle fatigue has been suggested as a factor in upper airway collapse, but there is little convincing evidence for this hypothesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SITES OF OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway obstruction does not necessarily occur at the site of anatomic narrowing. The narrowed site may have a regional compliance that prevents upper airway obstruction at the site, but creates a fall in downstream pressures that is sufficient to cause airway obstruction at a more caudal site.",
"   </p>",
"   <p>",
"    The oropharynx is the most common site of upper airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. However, 80 percent of patients have either multiple primary closure sites or one primary and one or more secondary closure sites (ie, sites that do not close until the primary closure site is remove surgically), according to a study that used pressure catheters inserted at different levels of the upper airway and visual inspection via fiberoptic endoscopy to identify upper airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24454/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24566050\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive collapse of the upper airway during sleep is the defining feature of obstructive sleep apnea (OSA), a disorder that is characterized by obstructive apneas and hypopneas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upper airway narrowing during sleep is normal. Among the factors that contribute to normal airway narrowing during sleep are a decreased neural drive to the respiratory muscles, a reduction in upper airway compensatory reflexes, and a supine sleep position. (See",
"      <a class=\"local\" href=\"#H24566144\">",
"       'Normal upper airway narrowing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When certain factors become superimposed upon those that cause normal upper airway narrowing, upper airway obstruction may result. Upper airway obstruction causes the obstructive apneas and hypopneas that define OSA. The superimposed factors may be categorized as either anatomic or neural. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Upper airway obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomic factors are abnormalities that cause a portion of the upper airway to become narrow. The increased resistance caused by the narrowing creates a pressure gradient across the narrowed site. The low pressure portion of the upper airway is then at increased risk for obstruction when the muscle tone is reduced during sleep. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Anatomic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major neural factor is activation of the upper airway dilator muscles, which causes upper airway obstruction because the upper airway is not sufficiently held open against the inspiratory forces. Other neural factors may include leptin resistance and repeated trauma to the mucosa and tissue of the upper airway. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neural factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The oropharynx is the most common site of upper airway obstruction. However, most patients have either multiple primary closure sites or one primary and one or more secondary closure sites. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Sites of obstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/1\">",
"      Hudgel DW, Martin RJ, Johnson B, Hill P. Mechanics of the respiratory system and breathing pattern during sleep in normal humans. J Appl Physiol 1984; 56:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/2\">",
"      Kay A, Trinder J, Kim Y. Individual differences in relationship between upper airway resistance and ventilation during sleep onset. J Appl Physiol 1995; 79:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/3\">",
"      Orem J, Osorio I, Brooks E, Dick T. Activity of respiratory neurons during NREM sleep. J Neurophysiol 1985; 54:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/4\">",
"      Issa FG, Sullivan CE. Alcohol, snoring and sleep apnea. J Neurol Neurosurg Psychiatry 1982; 45:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/5\">",
"      Fenik V, Kubin L, Okabe S, et al. Differential sensitivity of laryngeal and pharyngeal motoneurons to iontophoretic application of serotonin. Neuroscience 1997; 81:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/6\">",
"      Veasey SC, Panckeri KA, Hoffman EA, et al. The effects of serotonin antagonists in an animal model of sleep-disordered breathing. Am J Respir Crit Care Med 1996; 153:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/7\">",
"      Tangel DJ, Mezzanotte WS, Sandberg EJ, White DP. Influences of NREM sleep on the activity of tonic vs. inspiratory phasic muscles in normal men. J Appl Physiol 1992; 73:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/8\">",
"      Pierce R, White D, Malhotra A, et al. Upper airway collapsibility, dilator muscle activation and resistance in sleep apnoea. Eur Respir J 2007; 30:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/9\">",
"      Tangel DJ, Mezzanotte WS, White DP. Influence of sleep on tensor palatini EMG and upper airway resistance in normal men. J Appl Physiol 1991; 70:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/10\">",
"      Chan E, Steenland HW, Liu H, Horner RL. Endogenous excitatory drive modulating respiratory muscle activity across sleep-wake states. Am J Respir Crit Care Med 2006; 174:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/11\">",
"      Mezzanotte WS, Tangel DJ, White DP. Waking genioglossal electromyogram in sleep apnea patients versus normal controls (a neuromuscular compensatory mechanism). J Clin Invest 1992; 89:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/12\">",
"      Horner RL, Innes JA, Morrell MJ, et al. The effect of sleep on reflex genioglossus muscle activation by stimuli of negative airway pressure in humans. J Physiol 1994; 476:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/13\">",
"      Fogel RB, Trinder J, Malhotra A, et al. Within-breath control of genioglossal muscle activation in humans: effect of sleep-wake state. J Physiol 2003; 550:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/14\">",
"      Martin SE, Marshall I, Douglas NJ. The effect of posture on airway caliber with the sleep-apnea/hypopnea syndrome. Am J Respir Crit Care Med 1995; 152:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/15\">",
"      Stanchina ML, Malhotra A, Fogel RB, et al. The influence of lung volume on pharyngeal mechanics, collapsibility, and genioglossus muscle activation during sleep. Sleep 2003; 26:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/16\">",
"      Van de Graaff WB. Thoracic influence on upper airway patency. J Appl Physiol 1988; 65:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/17\">",
"      Chiu KL, Ryan CM, Shiota S, et al. Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. Am J Respir Crit Care Med 2006; 174:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/18\">",
"      Redolfi S, Yumino D, Ruttanaumpawan P, et al. Relationship between overnight rostral fluid shift and Obstructive Sleep Apnea in nonobese men. Am J Respir Crit Care Med 2009; 179:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/19\">",
"      Schwab RJ, Gupta KB, Gefter WB, et al. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 1995; 152:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/20\">",
"      Schwab RJ, Pasirstein M, Kaplan L, et al. Family aggregation of upper airway soft tissue structures in normal subjects and patients with sleep apnea. Am J Respir Crit Care Med 2006; 173:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/21\">",
"      Winter WC, Gampper T, Gay SB, Suratt PM. Enlargement of the lateral pharyngeal fat pad space in pigs increases upper airway resistance. J Appl Physiol 1995; 79:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/22\">",
"      Fogel RB, Malhotra A, Dalagiorgou G, et al. Anatomic and physiologic predictors of apnea severity in morbidly obese subjects. Sleep 2003; 26:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/23\">",
"      Hudgel DW, Harasick T. Fluctuation in timing of upper airway and chest wall inspiratory muscle activity in obstructive sleep apnea. J Appl Physiol 1990; 69:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/24\">",
"      Leiter JC, Knuth SL, Bartlett D Jr. The effect of sleep deprivation on activity of the genioglossus muscle. Am Rev Respir Dis 1985; 132:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/25\">",
"      O'donnell CP, Schaub CD, Haines AS, et al. Leptin prevents respiratory depression in obesity. Am J Respir Crit Care Med 1999; 159:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/26\">",
"      Boyd JH, Petrof BJ, Hamid Q, et al. Upper airway muscle inflammation and denervation changes in obstructive sleep apnea. Am J Respir Crit Care Med 2004; 170:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/27\">",
"      Nguyen AT, Jobin V, Payne R, et al. Laryngeal and velopharyngeal sensory impairment in obstructive sleep apnea. Sleep 2005; 28:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/28\">",
"      Guilleminault C, Li K, Chen NH, Poyares D. Two-point palatal discrimination in patients with upper airway resistance syndrome, obstructive sleep apnea syndrome, and normal control subjects. Chest 2002; 122:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/29\">",
"      Kimoff RJ, Sforza E, Champagne V, et al. Upper airway sensation in snoring and obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/30\">",
"      McNicholas WT, Coffey M, McDonnell T, et al. Upper airway obstruction during sleep in normal subjects after selective topical oropharyngeal anesthesia. Am Rev Respir Dis 1987; 135:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/31\">",
"      Horner RL, Shea SA, McIvor J, Guz A. Pharyngeal size and shape during wakefulness and sleep in patients with obstructive sleep apnoea. Q J Med 1989; 72:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/32\">",
"      Morrell MJ, Arabi Y, Zahn B, Badr MS. Progressive retropalatal narrowing preceding obstructive apnea. Am J Respir Crit Care Med 1998; 158:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/33\">",
"      Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 2003; 168:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24454/abstract/34\">",
"      Morrison DL, Launois SH, Isono S, et al. Pharyngeal narrowing and closing pressures in patients with obstructive sleep apnea. Am Rev Respir Dis 1993; 148:606.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7712 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24454=[""].join("\n");
var outline_f23_56_24454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24566050\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24566144\">",
"      Normal upper airway narrowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Anatomic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neural factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SITES OF OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24566050\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7712|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/57/28573\" title=\"figure 1\">",
"      Upper airway resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/59/40892\" title=\"figure 2\">",
"      Sleep tonic muscle activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42396\" title=\"figure 3\">",
"      Body position and airway size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/31/29182\" title=\"figure 4\">",
"      Sleep effect muscle training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7712|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39199\" title=\"picture 1\">",
"      Tonsillar hypertrophy OSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24455="Mitochondrial pathways congenital sideroblastic anemias";
var content_f23_56_24455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Mitochondrial pathways in the erythroblast affected by genetic defects of congenital sideroblastic anemias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 522px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A38: SLC25A38; CoA: coenzyme A; ALA: 5-aminolevulinic acid; CP&rsquo;gen III: coproporphyrinogen III; PPIX: protoporphyrin IX;&nbsp;Fe: iron;&nbsp;MFRN1: mitoferrin 1; Fe-S: iron-sulfur; ABCB7: mitochondrial transporter for cytosolic Fe-S cluster maturation; Thiamine-P-P: thiamine pyrophosphate; tRNA: transfer RNA; mt: mitochondrial; ALAS2: 5-aminolevulinate synthase; SLC25A38: mitochondrial amino acid carrier protein; GLRX5: glutaredoxin 5; FECH: ferrochelatase; PUS1: pseudouridine synthase; YARS2: tyrosyl-tRNA synthetase; SLC19A2: high affinity thiamine transporter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24455=[""].join("\n");
var outline_f23_56_24455=null;
var title_f23_56_24456="Anterior knee anatomy";
var content_f23_56_24456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65193%7EPEDS%2F51102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65193%7EPEDS%2F51102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Anterior anatomy of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior view of the knee with the patella removed, demonstrating the relationship between the bones, menisci, and major ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of the knee anatomy demonstrating the relationship between the bones, tendons, and bursae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24456=[""].join("\n");
var outline_f23_56_24456=null;
var title_f23_56_24457="Etiology, clinical manifestations, and diagnosis of volume depletion in adults";
var content_f23_56_24457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24457/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24457/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24457/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/56/24457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a variety of clinical disorders, fluid losses reduce extracellular fluid volume, potentially compromising tissue perfusion. Early diagnosis and prompt treatment to restore euvolemia can be lifesaving.",
"   </p>",
"   <p>",
"    True volume depletion may occur when sodium-containing fluids are lost in the urine, from the gastrointestinal tract or skin, or by acute sequestration into an internal \"third-space\" that results in a&nbsp;diminished intravascular&nbsp;volume.",
"   </p>",
"   <p>",
"    When these fluid losses occur, two factors serve to protect against the development of hypovolemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary sodium and water intake are generally far above basal needs. As a result, relatively large losses must occur unless intake is concomitantly reduced (as with anorexia or vomiting).",
"     </li>",
"     <li>",
"      The kidney minimizes urinary losses by enhancing sodium and water reabsorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the etiology, clinical manifestations, and diagnosis of volume depletion. The treatment of this disorder is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion results from loss of sodium and water from the following anatomic sites:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal losses, including vomiting, diarrhea, bleeding, and external drainage",
"     </li>",
"     <li>",
"      Renal losses, including the effects of diuretics, osmotic diuresis, salt-wasting nephropathies, and hypoaldosteronism",
"     </li>",
"     <li>",
"      Skin losses, including sweat, burns, and other dermatological conditions",
"     </li>",
"     <li>",
"      Third-space sequestration, including intestinal obstruction, crush injury, fracture, and acute pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastrointestinal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each day, approximately 3 to 6 liters of fluid are secreted by the stomach, pancreas, gallbladder, and intestines into the lumen of the gastrointestinal tract. Almost all of the secreted fluid is reabsorbed, so that only 100 to 200 mL are lost in the stool. However, volume depletion may ensue if the secreted fluid cannot be reabsorbed (as with external drainage and vomiting) or if secretion exceeds the capacity for reabsorption due either to increased&nbsp;secretion or reduced reabsorption. Acute bleeding from any site in the gastrointestinal tract is another common cause of volume depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal conditions, renal sodium and water excretion is adjusted to match intake. In a normal adult, approximately 130 to 180 liters is filtered across the glomerular capillaries each day. More than 98 to 99 percent of the filtrate is then reabsorbed by the tubules, resulting in a urine output averaging 1 to 2",
"    <span class=\"nowrap\">",
"     L/day.",
"    </span>",
"    Thus, a small (1 to 2 percent) reduction in tubular reabsorption can lead to a 2- to 4-liter increase in sodium and water excretion, which, if not replaced, can result in severe volume depletion.",
"   </p>",
"   <p>",
"    Diuretic therapy and osmotic diuresis caused by glucosuria are the most common causes of excessive renal salt and water loss. Variable degrees of sodium wasting are also present in many different renal diseases. As an example, most patients with chronic kidney disease and a glomerular filtration rate (GFR) of less than 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    are unable to maximally conserve sodium if acutely placed on a low-sodium diet. These patients may have an obligatory sodium loss of 10 to 40",
"    <span class=\"nowrap\">",
"     meq/day,",
"    </span>",
"    in contrast to normal subjects who can lower sodium excretion to less than 5",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This degree of sodium wasting is usually not important since normal sodium balance is maintained as long as the patient is on a regular diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of polyuria and diabetes insipidus\", section on 'Salt-wasting nephropathy: not a cause of polyuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rare patients may have a severe salt-wasting nephropathy with obligatory urinary losses that may exceed 100 meq of sodium and 2 liters of water per day. Such patients develop hypovolemia unless a high sodium intake is maintained. Severe salt-wasting nephropathy is most often seen in tubular and interstitial diseases, such as autosomal dominant interstitial kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sweat production is low in the basal state, it can exceed 1 to 2",
"    <span class=\"nowrap\">",
"     L/h",
"    </span>",
"    in a subject exercising in a hot, dry climate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skin also acts as a barrier that prevents the loss of interstitial fluid to the external environment. When this barrier is interrupted by burns or exudative skin lesions, a large volume of fluid can be lost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sequestration into a third-space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion can be produced by the loss of interstitial and intravascular fluid into a third-space that is not in equilibrium with the extracellular fluid. As an example, a patient with a fractured hip may lose 1500 to 2000 mL of blood into the tissues adjacent to the fracture. Although this fluid will be resorbed back into the extracellular fluid over a period of days to weeks, the acute reduction in blood volume, if not replaced, can lead to severe volume depletion. Other examples of third-space fluid losses include intestinal obstruction, severe pancreatitis, crush injuries, bleeding (as with trauma or a ruptured abdominal aortic aneurysm), peritonitis, and obstruction of a major venous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic patients may present with a variety of symptoms, physical examination findings, and laboratory abnormalities. Symptoms may be related to the volume depletion itself, such as lassitude and postural dizziness, or to the underlying cause of volume depletion, such as vomiting, diarrhea, or polyuria. The physical examination may reveal decreased skin turgor, low arterial blood pressure or postural hypotension, and reduced jugular venous pressure. Patients with hypovolemia may present with a variety of laboratory abnormalities, including an elevated serum creatinine and blood urea nitrogen (BUN), hypernatremia or hyponatremia, hyperkalemia or hypokalemia, and metabolic alkalosis or metabolic acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three sets of symptoms may occur in hypovolemic patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those due to volume depletion",
"     </li>",
"     <li>",
"      Those related to the cause of fluid loss",
"     </li>",
"     <li>",
"      Those due to the electrolyte and acid-base disorders that can accompany volume depletion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Symptoms related to volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms induced by hypovolemia are primarily related to decreased tissue perfusion. The earliest complaints include lassitude, easy fatigability, thirst, muscle cramps, and postural dizziness. More severe fluid loss can lead to abdominal pain, chest pain, or lethargy and confusion due to ischemia of the mesenteric, coronary, or cerebral vascular beds, respectively. These symptoms are usually reversible, although tissue necrosis may develop if the low-flow state is allowed to persist.",
"   </p>",
"   <p>",
"    Patients may also report decreased urine volume or frequency. Low urine volume (oliguria) in is common in hypovolemic patients due to the combination of sodium and water avidity. If, however, concentrating ability is impaired, oliguria may not be present.",
"   </p>",
"   <p>",
"    Symptomatic hypovolemia most often occurs in patients with isosmotic sodium and water depletion in whom most of the fluid deficit comes from the extracellular fluid. This contrasts with pure water loss due to insensible losses or diabetes insipidus, in which the elevation in the plasma osmolality (and sodium concentration) causes water to move down an osmotic gradient from the cells into the extracellular fluid. The net result of pure water loss is that approximately two-thirds of the water lost comes from the intracellular fluid, a condition which is called \"dehydration\" rather than \"hypovolemia\". Patients with pure water losses exhibit the symptoms of hypernatremia (produced by the water deficit) before those of marked extracellular fluid depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Definitions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Symptoms related to the cause of fluid loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypovolemia will often have symptoms related to the cause of the fluid losses. These symptoms may include vomiting, diarrhea, polyuria, a severe skin burn, or, in the case of sequestration into a third-space, pain associated with the underlying etiology. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Symptoms related to electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of electrolyte and acid-base disorders may also occur in hypovolemic patients, depending upon the composition of the fluid that is lost. The more serious symptoms and associated abnormalities include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle weakness due to hypokalemia or hyperkalemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"       \"Approach to the patient with muscle weakness\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Polyuria and polydipsia due to severe hypokalemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3819925#H3819925\">",
"       \"Clinical manifestations and treatment of hypokalemia\", section on 'Renal abnormalities'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tachypnea due to acidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"       \"Approach to the adult with metabolic acidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuromuscular irritability and confusion due to metabolic alkalosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link\">",
"       \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lethargy, confusion, seizures, and coma due to hyponatremia or hypernatremia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"       \"Manifestations of hyponatremia and hypernatremia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional symptom that occurs only in primary adrenal insufficiency is extreme salt craving. Patients with this disease frequently give a history of heavily salting all foods (including those not usually salted) and even of eating salt that they have sprinkled on their hands. The mechanism responsible for this appropriate increase in salt intake is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although relatively insensitive and nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/4\">",
"     4",
"    </a>",
"    ], certain findings on physical examination may suggest volume depletion. A decrease in the interstitial volume can be detected by the examination of the skin and mucous membranes, while a decrease in the plasma volume can lead to reductions in the systemic blood pressure and the venous pressure in the jugular veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Skin and mucous membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the skin on the thigh, calf, or forearm is pinched in normal subjects, it will immediately return to its normally flat state when the pinch is released. This elastic property, called turgor, is partially dependent upon the interstitial volume of the skin and subcutaneous tissue. Interstitial fluid loss leads to diminished skin turgor, and the skin flattens more slowly after the pinch is released. In younger patients, the presence of decreased skin turgor is a reliable indicator of volume depletion. By comparison, elasticity diminishes with age, so that reduced skin turgor does not necessarily reflect hypovolemia in older patients (more than 55 to 60 years old). In these patients, skin elasticity is usually best preserved on the inner aspect of the thighs and the skin overlying the sternum. Decreased turgor at these sites is suggestive of volume depletion (see below).",
"   </p>",
"   <p>",
"    Although reduced skin turgor is an important clinical finding, normal turgor does not exclude the presence of hypovolemia. This is particularly true with mild volume deficits, in young patients whose skin is very elastic, and in obese patients, since fat deposits under the skin prevent the changes in subcutaneous turgor from being appreciated.",
"   </p>",
"   <p>",
"    The skin is also usually dry in hypovolemic patients, and a dry axilla is particularly suggestive of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/4\">",
"     4",
"    </a>",
"    ]. The tongue and oral mucosa may also be dry since salivary secretions are commonly decreased in this setting.",
"   </p>",
"   <p>",
"    Examination of the skin may be helpful in the diagnosis of primary adrenal insufficiency. The impaired release of cortisol leads to hypersecretion of ACTH, which can result in increased pigmentation of the skin, especially in the palmar creases and buccal mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Arterial blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arterial blood pressure changes from near normal with mild hypovolemia to low in the upright position and then, with progressive volume depletion, to persistently low regardless of posture. Postural hypotension leading to dizziness may be the patient's major complaint and is strongly suggestive of hypovolemia in the absence of an autonomic neuropathy or the use of sympatholytic drugs for hypertension.",
"   </p>",
"   <p>",
"    An important change that can occur with marked fluid loss is that the secondary neurohumoral vasoconstriction leads to decreased intensity of both the Korotkoff sounds (when the blood pressure is being measured with a sphygmomanometer) and the radial pulse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As a result, a very low blood pressure suggested by auscultation or palpation may actually be associated with a near-normal pressure when measured directly by an intraarterial catheter.",
"   </p>",
"   <p>",
"    It should be noted that the definition of normal blood pressure in this setting is dependent upon the patient's usual value. Although",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg is considered \"normal\", it is actually low in a hypertensive patient whose blood pressure is commonly",
"    <span class=\"nowrap\">",
"     180/100",
"    </span>",
"    mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Jugular venous pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in the vascular volume observed with hypovolemia occurs primarily in the venous circulation (which normally contains 70 percent of the blood volume), thereby leading to a decrease in venous pressure. In most patients, the venous pressure can be estimated with sufficient accuracy by physical examination. The height of the jugular venous pulse above the right atrium (5 cm above the sternal angle of Louis) approximates the atrial pressure. However, characterization of the venous pressure as either low (less than or equal to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0) or high (greater than or equal to10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0) is probably as precise an estimate as can be achieved.",
"   </p>",
"   <p>",
"    Theoretically, the internal jugular vein would provide a more accurate reflection of right atrial pressure than the external jugular vein because of its larger diameter, less tortuous course, and absence of valves. However, pulsations of the external jugular vein are more easily seen and inspection of this venous pulse alone has been shown to correlate with direct measurements made by a central venous catheter positioned in the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic patients can have a variety of abnormal results of routinely performed laboratory tests. In addition to suggesting the presence of volume depletion, these changes may provide important clues to the etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Low urine volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the urine volume is typically, but not always, low (oliguria) in hypovolemic patients due to the combination of sodium and water avidity. If, however, concentrating ability is impaired, oliguria may not be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Elevation of the BUN and serum creatinine concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most circumstances, the BUN and serum creatinine concentration vary inversely with the glomerular filtration rate (GFR), increasing as the GFR falls. Serial measurements of these parameters can be used to assess the course of renal disease. However, an elevation in the BUN can also be produced by an increase in the rate of urea production or tubular reabsorption. As a result, the serum creatinine concentration is a more reliable estimate of the GFR since it is produced at a relatively constant rate by skeletal muscle and is not reabsorbed by the renal tubules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In normal subjects and those with uncomplicated renal disease, the",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine ratio is approximately 10:1. However, this value may be substantially elevated in hypovolemic states because of the associated increase in urea reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/8\">",
"     8",
"    </a>",
"    ]. In general, about 40 to 50 percent of filtered urea is reabsorbed, much of this occurring in the proximal tubule, where it is passively linked to the reabsorption of sodium and water. Thus, the increase in proximal sodium reabsorption in volume depletion produces a parallel increase in urea reabsorption. The net effect is a fall in urea excretion and elevations in the BUN and the",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine ratio, frequently to greater than 20:1. This selective rise in the BUN is called prerenal azotemia. The serum creatinine concentration will increase in this setting only if the degree of hypovolemia is severe enough to lower the GFR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although an elevated",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine may indicate hypovolemia, it is subject to misinterpretation for two major reasons: 1) the BUN is affected by the rate of urea production; a high ratio may be due solely to increased urea production (as with steroid therapy) rather than hypovolemia, whereas a normal ratio may occur in patients with hypovolemia if urea production is reduced (eg, due to decreased protein intake); 2) the serum creatinine is affected by muscle mass as well as GFR; a high ratio may be due to a low muscle mass (which lowers the serum creatinine concentration), increasing the",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine ratio in the absence of hypovolemia.",
"   </p>",
"   <p>",
"    A special case is the increased",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine ratio in patients with upper gastrointestinal bleeding. In such patients, the ratio increases markedly for two reasons: the extracellular fluid volume is decreased due to the blood loss, which increases proximal tubule urea reabsorption; and the rate of urea production is increased due to the catabolism and absorption of blood proteins from the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hypernatremia and hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors can influence the serum sodium concentration in hypovolemic states, and it is the interplay between them that determines the level observed in a given patient. Primary water loss, as in insensible losses or diabetes insipidus, results in hypernatremia. On the other hand, salt and water loss may be associated with hyponatremia. Volume depletion stimulates the release of antidiuretic hormone (ADH), which will tend to cause retention of ingested water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Hypokalemia and hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either hypokalemia or hyperkalemia can occur in hypovolemic patients. The former is much more common because of potassium loss from the gastrointestinal tract or in the urine. However, there may be an inability to excrete the dietary potassium load in the urine because of renal failure, hypoaldosteronism, or volume depletion itself, since the delivery of sodium and water to the potassium secretory site in the cortical collecting tubule will be reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Metabolic alkalosis and acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of fluid loss on acid-base balance also is variable. Although many patients maintain a normal extracellular pH, either metabolic alkalosis or metabolic acidosis can occur. Patients with vomiting or nasogastric suction or those given diuretics tend to develop metabolic alkalosis because of hydrogen ion loss and volume contraction. On the other hand, bicarbonate loss (due to diarrhea or intestinal fistulas) can lead to metabolic acidosis. In addition, lactic acidosis can occur in shock and ketoacidosis in uncontrolled diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Hematocrit and serum albumin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since red blood cells and albumin are essentially limited to the vascular space, a reduction in the plasma volume due to volume depletion tends to elevate both the hematocrit (ie, relative polycythemia) and serum albumin concentration. However, these changes are frequently absent because of underlying hypoalbuminemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia, due, for example, to bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Manifestations of shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and physical findings that have been described apply to patients with mild to moderate volume depletion who are still able to maintain an adequate level of tissue perfusion. However, as the degree of hypovolemia becomes more severe, due, for example, to the loss of 30 percent of the blood volume from a ruptured aortic aneurysm, there is a marked reduction in tissue perfusion, resulting in a clinical syndrome referred to as hypovolemic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. This syndrome is associated with a marked increase in sympathetic activity and is characterized by tachycardia, cold, clammy extremities, cyanosis, a low urine output (usually less than 15",
"    <span class=\"nowrap\">",
"     mL/h),",
"    </span>",
"    and agitation and confusion due to reduced cerebral blood flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Manifestations in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike in younger individuals, excessive fluid loss in older individuals often presents with nonspecific signs and symptoms. The most specific for hypovolemia is acute weight loss; however, obtaining an accurate weight over time may be difficult in the elderly. Weight loss is particularly important to identify because the elderly, compared with the young, have a greater proportion of fat (relative to lean) muscle mass. Since there is less water in fat than in muscle, older individuals have a lower total body water (relative to weight) and therefore, for a given degree of fluid loss, will have a greater reduction in extracellular fluid volume.",
"   </p>",
"   <p>",
"    Many clinical signs and symptoms that would suggest volume depletion in a younger individual may be unreliable in the elderly. Postural hypotension, for example, is not uncommon in euvolemic elderly patients as a result of sympathetic dysfunction and poor physical conditioning. In addition, a dry tongue and mouth, muscle weakness, confusion, speech difficulty, and sunken eyes can occur in the elderly for many reasons other than volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the type of fluid lost and clinical setting, the elderly patient may have a normal, low, or high serum sodium concentration. Older individuals are particularly prone to hypernatremia because of impaired thirst mechanisms and an inability to increase water intake due to compromised mobility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swallowing ability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In almost all cases, hypovolemia is a clinical diagnosis based upon the characteristic manifestations mentioned above and confirmed by a",
"    <strong>",
"     low urine sodium concentration",
"    </strong>",
"    . (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An accurate history and physical examination not only provides evidence for the presence of volume depletion but may also help determine the etiology. In most individuals, the history should identify the source of fluid loss.",
"   </p>",
"   <p>",
"    In the elderly, however, the history may not identify the cause of hypovolemia. Such elements of the history may be absent in these patients because of confusion or cognitive issues.",
"   </p>",
"   <p>",
"    An additional problem is the frequent inability to detect relative hypovolemia in patients with underlying edematous disorders or renal failure. Although clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory abnormalities may suggest relative volume depletion in some cases, others may require empiric fluid replacement therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravascular monitoring to reverse the consequences of hypovolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780669\">",
"    <span class=\"h2\">",
"     Urine sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low urine sodium concentration (or low urine chloride concentration in patients who have metabolic alkalosis) is",
"    <strong>",
"     strongly suggestive",
"    </strong>",
"    of reduced tissue perfusion, and it is usually present in hypovolemic patients unless there is a salt-wasting state (eg, diuretics, underlying renal disease), selective renal ischemia (eg, acute glomerulonephritis or bilateral renal artery stenosis), or a very low-sodium diet.",
"   </p>",
"   <p>",
"    However, the presence of a low urine sodium does not necessarily mean that the patient has true volume depletion since edematous patients with heart failure, cirrhosis with ascites, and the nephrotic syndrome also avidly conserve sodium. These disorders are characterized by reduced effective arterial blood volume due to a primary reduction in cardiac output (heart failure), to splanchnic vasodilatation and sequestration of fluid in the peritoneal cavity and arterial shunts (cirrhosis), and to a low plasma oncotic pressure (in some patients with severe or acute nephrotic syndrome).",
"   </p>",
"   <p>",
"    The response of the kidney to true volume depletion and reduced effective arterial blood volume is to conserve sodium and water in an attempt to expand the extracellular volume. With the exception of those disorders in which sodium reabsorption is impaired, the urine sodium concentration in hypovolemic states should be less than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and may be as low as 1",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    There are two additional exceptions in which the urine sodium concentration may be higher than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    despite the presence of hypovolemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When there is also a high rate of water reabsorption; in this setting, the rate of sodium excretion and urine volume are low, but the urine sodium concentration is higher than expected due to concentration of the urine.",
"     </li>",
"     <li>",
"      When sodium is excreted with another anion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/11\">",
"       11",
"      </a>",
"      ]. This most often occurs in metabolic alkalosis due to vomiting or nasogastric suction. In such disorders, the metabolic alkalosis is associated with a high filtered bicarbonate load. The stimuli that increase renal sodium and bicarbonate reabsorption (volume depletion and hypokalemia) may sometimes be inadequate to remove all of the filtered sodium and bicarbonate from the urine. Under these conditions, urinary bicarbonate excretion occurs (with sodium as the accompanying cation). This occurs early in the disorder and also intermittently during established alkalosis, usually when transient further increases in serum bicarbonate occur (disequilibration phases of metabolic alkalosis). In such settings, the urine chloride concentration remains low (ie, below 20",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and is a better index of extracellular fluid volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link\">",
"       \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17231343\">",
"    <span class=\"h2\">",
"     Less specific laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory tests can provide evidence for the presence of hypovolemia or reduced effective arterial blood volume, but are less specific than a low urine sodium or chloride concentration. These include the fractional excretion of sodium, the urine osmolality and specific gravity, and the urinalysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780719\">",
"    <span class=\"h3\">",
"     Fractional excretion of sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to measurement of the urine sodium concentration is calculation of the fractional excretion of sodium (FENa) using either standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or SI units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). The FENa directly evaluates sodium handling and, in contrast to the urine sodium concentration, is not affected by changes in urine volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FENa is most useful in the differential diagnosis of oliguric acute kidney injury with a reduced glomerular filtration rate (GFR). In this setting, the FENa is usually under 1 percent in hypovolemic patients and above 1 percent when the oliguria is due to acute tubule necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. By comparison, this measurement is more difficult to evaluate in patients with a normal GFR since the filtered sodium load is so high in this setting that a different value (FENa &lt;0.1 to 0.2 percent) must be used to diagnose volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H713876789#H713876789\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'FENa varies with GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780908\">",
"    <span class=\"h3\">",
"     Urine osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hypovolemic states, the urine is relatively concentrated with an osmolality often exceeding 450",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. This response may not be seen, however, if concentrating ability is impaired by renal disease, an osmotic diuresis, the administration of diuretics, or central or nephrogenic diabetes insipidus. As an example, both severe volume depletion (which impairs urea accumulation in the renal medulla) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/15\">",
"     15",
"    </a>",
"    ] and hypokalemia (which induces antidiuretic hormone [ADH] resistance) can limit the increase in the urine osmolality in some patients. Thus, a high urine osmolality is consistent with hypovolemia, but a relatively isosmotic value does not exclude the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary concentration can also be assessed by measuring the specific gravity. The results are less reliable than the urine osmolality&nbsp;because specific gravity is&nbsp;determined&nbsp;by&nbsp;the&nbsp;mass rather than",
"    <strong>",
"    </strong>",
"    number of solute particles in the urine. A&nbsp;value above 1.015 is suggestive,&nbsp;but not diagnostic,&nbsp;of a concentrated urine, as is usually seen with hypovolemia.&nbsp;The urine specific gravity is misleadingly high&nbsp;with proteinuria or&nbsp;after administration of radiocontrast agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H413987#H413987\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Urine osmolality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781074\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the urine is an important diagnostic tool in patients with elevations in the BUN and plasma creatinine concentration. The urinalysis is generally normal in hypovolemic states since the kidney is not diseased. This is in contrast to most, but not all, of the other causes of renal insufficiency in which the urinalysis reveals protein, cells,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    casts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780529\">",
"    <span class=\"h2\">",
"     Central venous pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the left ventricular end-diastolic pressures (LVEDP), and not the right atrial pressure, that is the important determinant of left ventricular output which, together with vascular resistance, determines tissue perfusion. Although an estimate of central venous pressure can help determine a patient's volume status, the central venous pressure does",
"    <strong>",
"     not",
"    </strong>",
"    adequately predict whether or not an intravenous fluid challenge will increase stroke volume and cardiac index [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two major clinical settings in which the central venous or right atrial pressure provides an unreliable estimate of the LVEDP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with pure left-sided heart failure, the wedge pressure is increased, but the central venous pressure may remain unchanged if right ventricular function is normal. In this setting, treating a low central venous pressure with volume expanders can precipitate pulmonary edema.",
"     </li>",
"     <li>",
"      The central venous pressure tends to exceed the LVEDP in patients with pure right-sided heart failure (as with cor pulmonale or following an acute right-sided myocardial infarction). These patients may have high central venous pressures even in the presence of volume depletion; as a result, the central venous pressure cannot be used as a guide to therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=see_link\">",
"       \"Cor pulmonale\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17231445\">",
"    <span class=\"h2\">",
"     Diagnosis in certain clinical settings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congestive heart failure and hypovolemia share several biochemical features (a high",
"    <span class=\"nowrap\">",
"     BUN/creatinine",
"    </span>",
"    ratio and a low urine sodium concentration). Physical examination allows easy differentiation between the two conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, persistently edematous patients with congestive heart failure who are aggressively treated with diuretics may develop a fall in cardiac output due to relative volume depletion, and the decrease in tissue perfusion will result in a rise in the BUN. It can be difficult to distinguish clinically between progression of intrinsic heart disease and relative hypovolemia. Such patients may require a cautious therapeutic trial of saline infusion or placement of a pulmonary artery catheter for optimal fluid management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in congestive heart failure, the low urine sodium concentration found in cirrhotic patients with ascites and, in many cases, peripheral edema should not be confused with true volume depletion. The progressive vasodilation seen in cirrhosis leads to the activation of endogenous vasoconstrictors, sodium and water retention, and increasing renal vasoconstriction, thereby leading to a very low urine sodium concentration, hyponatremia, decreased tissue perfusion, and occasionally the hepatorenal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"     \"Diagnostic approach to the patient with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hepatorenal syndrome is a prerenal disease, as the kidneys are normal histologically and have been used successfully for renal transplantation. However, decreased renal perfusion in this setting can also be induced by concurrent volume losses, including gastrointestinal losses, bleeding, or overly aggressive diuretic therapy. As a result, diagnosis of the hepatorenal syndrome requires the lack of improvement in renal function following discontinuation of potential nephrotoxins and a trial of fluid repletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory diagnosis of hypovolemia may be difficult to establish in patients with underlying renal disease. In this setting, the urine sodium concentration may exceed 20",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and the urine osmolality may be less than 350",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    since renal insufficiency impairs the ability to maximally conserve sodium and to concentrate the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/14,17,18\">",
"     14,17,18",
"    </a>",
"    ]. In addition, the urinalysis may be abnormal due to the primary disease.",
"   </p>",
"   <p>",
"    Despite this difficulty, making the correct diagnosis is important since volume depletion is a reversible cause of worsening renal function, in contrast to progression of the underlying renal disease. The history and physical examination may be helpful in some patients, but these findings are not always present. As a result, a cautious trial of fluid repletion may be warranted in the patient whose renal function has deteriorated without obvious cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of intravascular volume depletion in the patient with nephrotic syndrome is particularly difficult. Despite a great deal of study, the relative roles of underfilling due to hypoalbuminemia and overflow due to renal sodium retention remain unclear and probably vary among patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Patients with \"underfill\" edema are more commonly those with a GFR greater than 75 percent of normal and with either minimal change disease of acute onset or severe hypoalbuminemia (often below 1",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The ability to distinguish between these two possibilities is extremely important, as diuretic therapy may be useful in those with elevated intravascular volumes but deleterious in patients with underfilling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although associated with nonspecific manifestations among the elderly, the findings of hypernatremia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss are suggestive for fluid loss. Additional helpful objective clinical signs, although less specific than in younger individuals, include an elevated BUN-to-creatinine ratio and a low urinary sodium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypotension is generally present in patients with shock, it is not required for the diagnosis since vasoconstriction sometimes maintains a relatively normal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24457/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Shock, independent of etiology, is characterized by tachycardia, cold, clammy extremities, cyanosis, a low urine output (usually less than 15",
"    <span class=\"nowrap\">",
"     mL/h),",
"    </span>",
"    and agitation and confusion due to reduced cerebral blood flow. Shock due to hypovolemia may be suggested by the history (whether obtained from the patient, observer, or family), physical examination, laboratory studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasive monitoring (including pulmonary artery catheterization). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       \"Patient information: Dehydration (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5036969\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a variety of clinical disorders, fluid losses reduce extracellular fluid volume, potentially compromising tissue perfusion. Early diagnosis and prompt treatment to restore euvolemia can be lifesaving. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Volume depletion results from loss of sodium and water from the following anatomic sites (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gastrointestinal losses, including vomiting, diarrhea, bleeding, and external drainage",
"     </li>",
"     <li>",
"      Renal losses, including the effects of diuretics, osmotic diuresis, salt-wasting nephropathies, and hypoaldosteronism",
"     </li>",
"     <li>",
"      Skin losses, including sweat, burns, and other dermatological conditions",
"     </li>",
"     <li>",
"      Third-space sequestration, including intestinal obstruction, crush injury, fracture, and acute pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemic patients may present with a variety of symptoms, physical examination findings, and laboratory abnormalities. Symptoms may be related to the volume depletion itself, such as lassitude and postural dizziness, or to the underlying cause of volume depletion, such as vomiting, diarrhea, or polyuria. The physical examination may reveal decreased skin turgor, low arterial blood pressure or postural hypotension, and reduced jugular venous pressure. Patients with hypovolemia may present with a variety of laboratory abnormalities, including an elevated serum creatinine and blood urea nitrogen (BUN), hypernatremia or hyponatremia, hyperkalemia or hypokalemia, and metabolic alkalosis or metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the degree of hypovolemia becomes more severe, there is a marked reduction in tissue perfusion, resulting in a clinical syndrome referred to as hypovolemic shock. This syndrome is associated with a marked increase in sympathetic activity and is characterized by tachycardia, cold, clammy extremities, cyanosis, a low urine output, and agitation and confusion due to reduced cerebral blood flow. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Manifestations of shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike in younger individuals, excessive fluid loss in older individuals often presents with nonspecific signs and symptoms. The most specific for hypovolemia is acute weight loss; however, obtaining an accurate weight over time may be difficult in the elderly. Many clinical signs and symptoms that would suggest volume depletion in a younger individual may be unreliable in the elderly. Postural hypotension, for example, is not uncommon in euvolemic elderly patients as a result of sympathetic dysfunction and poor physical conditioning. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Manifestations in the elderly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In almost all cases, hypovolemia is a clinical diagnosis based upon the characteristic manifestations mentioned above and confirmed by a",
"      <strong>",
"       low urine sodium concentration",
"      </strong>",
"      . An accurate history and physical examination not only provides evidence for the presence of volume depletion but may also help determine the etiology. In most individuals, the history should identify the source of fluid loss. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A low urine sodium concentration is",
"      <strong>",
"       strongly suggestive",
"      </strong>",
"      of reduced tissue perfusion, and it is usually present in hypovolemic patients unless there is a salt-wasting state (eg, diuretics, underlying renal disease), selective renal ischemia (eg, acute glomerulonephritis or bilateral renal artery stenosis), or a very low-sodium diet. There are two additional exceptions in which the urine sodium concentration may be higher than 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      despite the presence of hypovolemia (see",
"      <a class=\"local\" href=\"#H780669\">",
"       'Urine sodium concentration'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When there is also a high rate of water reabsorption; in this setting, the rate of sodium excretion and urine volume are low, but the urine sodium concentration is higher than expected due to concentration.",
"     </li>",
"     <li>",
"      When sodium is excreted with another anion; this is most often seen in metabolic alkalosis (due, for example, to vomiting), where the need to excrete the excess bicarbonate (as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      ) may raise the urine sodium concentration despite the presence of volume depletion. In this setting, the urine chloride concentration remains low (ie, below 20",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and is frequently a better index of volume status.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/1\">",
"      Coleman AJ, Arias M, Carter NW, et al. The mechanism of salt wastage in chronic renal disease. J Clin Invest 1966; 45:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/2\">",
"      Danovitch GM, Bourgoignie J, Bricker NS. Reversibility of the \"salt-losing\" tendency of chronic renal failure. N Engl J Med 1977; 296:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/3\">",
"      Better OS. Impaired fluid and electrolyte balance in hot climates. Kidney Int 1987; 32:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/4\">",
"      McGee S, Abernethy WB 3rd, Simel DL. The rational clinical examination. Is this patient hypovolemic? JAMA 1999; 281:1022.",
"     </a>",
"    </li>",
"    <li>",
"     Weil MH, von Planta M, Rackow EC. Acute circulatory failure (shock). In: Heart Disease. A Textbook of Cardiovascular Medicine, Braunwald E (Ed), Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/6\">",
"      Cohn JN. Blood pressure measurement in shock. Mechanism of inaccuracy in ausculatory and palpatory methods. JAMA 1967; 199:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/7\">",
"      Vinayak AG, Levitt J, Gehlbach B, et al. Usefulness of the external jugular vein examination in detecting abnormal central venous pressure in critically ill patients. Arch Intern Med 2006; 166:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/8\">",
"      Dossetor JB. Creatininemia versus uremia. The relative significance of blood urea nitrogen and serum creatinine concentrations in azotemia. Ann Intern Med 1966; 65:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/9\">",
"      Baskett, PJF. ABC of major trauma. Management of hypovolaemic shock. Br Med J 1990; 300:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/10\">",
"      Cohn, JN. Blood pressure measurement in shock: Mechanism of inaccuracy in auscultatory and palpatory methods. J Am Med Assoc 1967; 199:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/11\">",
"      Sherman RA, Eisinger RP. The use (and misuse) of urinary sodium and chloride measurements. JAMA 1982; 247:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/12\">",
"      Miller TR, Anderson RJ, Linas SL, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 1978; 89:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/13\">",
"      Espinel CH, Gregory AW. Differential diagnosis of acute renal failure. Clin Nephrol 1980; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York City 1987. p.82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/15\">",
"      LEVINSKY NG, DAVIDSON DG, BERLINER RW. Effects of reduced glomerular filtration on urine concentration in the presence of antidiuretic hormone. J Clin Invest 1959; 38:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/16\">",
"      Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/17\">",
"      Danovitch GM, Bourgoignie JJ, Bricker NS, et al. Reversibility of the \"salt-losing\" tendency of chronic renal failure. N Engl J Med 1977; 296:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/18\">",
"      DORHOUT MEES EJ. Relation between maximal urine concentration, maximal water reabsorption capacity, and mannitol clearance in patients with renal disease. Br Med J 1959; 1:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/19\">",
"      Meltzer JI, Keim HJ, Laragh JH, et al. Nephrotic syndrome: vasoconstriction and hypervolemic types indicated by renin-sodium profiling. Ann Intern Med 1979; 91:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/20\">",
"      Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998; 53:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/21\">",
"      Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24457/abstract/22\">",
"      Vande Walle JG, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J Am Soc Nephrol 1999; 10:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2298 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24457=[""].join("\n");
var outline_f23_56_24457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5036969\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastrointestinal losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sequestration into a third-space",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Symptoms related to volume depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Symptoms related to the cause of fluid loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Symptoms related to electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Skin and mucous membranes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Arterial blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Jugular venous pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Low urine volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Elevation of the BUN and serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hypernatremia and hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Hypokalemia and hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Metabolic alkalosis and acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Hematocrit and serum albumin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Manifestations of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Manifestations in the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H780669\">",
"      Urine sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17231343\">",
"      Less specific laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H780719\">",
"      - Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H780908\">",
"      - Urine osmolality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H781074\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H780529\">",
"      Central venous pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17231445\">",
"      Diagnosis in certain clinical settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5036969\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24458="Cerebrovascular disorders complicating pregnancy";
var content_f23_56_24458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerebrovascular disorders complicating pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Men-Jean Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Susan Hickenbottom, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/56/24458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/56/24458/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/56/24458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease during pregnancy can be distilled into two major categories:",
"    <span class=\"nowrap\">",
"     thrombosis/ischemia",
"    </span>",
"    (including arterial and venous infarction) and hemorrhage (including intracerebral and subarachnoid hemorrhage). Normal physiologic changes associated with pregnancy, combined with pathophysiologic processes unique to pregnancy, predispose women to develop stroke during pregnancy and the puerperium.",
"   </p>",
"   <p>",
"    This topic review will focus on the relationship between pregnancy and cerebrovascular disorders. Other neurologic disorders complicating pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20634?source=see_link\">",
"     \"Neurologic disorders complicating pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant or recently pregnant women develop stroke (incidence 11 to 34 per 100,000 deliveries) more frequently than their nonpregnant counterparts (annual incidence, 10.7 per 100,000 women of reproductive age) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Approximately 10 percent of strokes occur in the antepartum period, 40 percent occur proximate to delivery, and 50 percent occur postpartum and after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/2\">",
"     2",
"    </a>",
"    ]. Although data are inconsistent, the incidence of stroke during the antenatal period alone, excluding stroke during the puerperium, may be similar to the incidence in nonpregnant women of childbearing age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, pregnancy and the postpartum period are associated with a marked increase in the relative risk and a small increase in the absolute risk of ischemic stroke and intracerebral hemorrhage, with the highest risk during the puerperium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. This was illustrated in a review of female hospital discharges from central Maryland and Washington, DC in 1988 and 1991 that determined the magnitude of the effect of pregnancy (including spontaneous and induced abortions) on stroke risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/5\">",
"     5",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For cerebral infarction, the relative risk was 0.7 during pregnancy (a nonsignificant difference) but increased to 8.7 in the postpartum period (within six weeks of a live birth or stillbirth).",
"     </li>",
"     <li>",
"      For intracerebral hemorrhage, the adjusted relative risk was 2.5 during pregnancy but increased to 28.3 in the postpartum period.",
"     </li>",
"     <li>",
"      For both types of stroke, which occurred with equal frequency, the excess risk during the postpartum period was only 8.1 strokes per 100,000 pregnancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were reported in a large study from France [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/6\">",
"     6",
"    </a>",
"    ] and in an analysis from the Nationwide Inpatient Sample of all pregnancy-related discharges in the United States from 2000 to 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are conflicting regarding the occurrence of aneurysmal subarachnoid hemorrhage during pregnancy, delivery, and the postpartum period. Some studies have reported an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], while others concluded that aneurysmal rupture is not more frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the available data suggest that the risk of hemorrhage from a cerebral arteriovenous malformation is not increased during pregnancy, but the issue is controversial, and no definitive data exist [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/13\">",
"     13",
"    </a>",
"    ]. One of the better studies was a retrospective analysis of 451 women with a brain arteriovenous malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/14\">",
"     14",
"    </a>",
"    ]. The hemorrhage rate in pregnant women in this population was not significantly different compared with the rate for nonpregnant women (3.5 versus 3.1 percent per person-year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for stroke related to pregnancy include cesarean delivery, pregnancy-induced hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/9\">",
"     9",
"    </a>",
"    ], postpartum infection, [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/2\">",
"     2",
"    </a>",
"    ], and possibly multiple gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/15\">",
"     15",
"    </a>",
"    ], although the latter has not been evaluated as an independent risk factor.",
"   </p>",
"   <p>",
"    In addition, several conditions that are unique to pregnancy can present as either a stroke or a stroke-like event. These include",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    postpartum cerebral angiopathy, and gestational trophoblastic disease. Amniotic fluid embolism is an important cause of pregnancy-related morbidity and mortality, but is thought to be a rare cause of focal cerebral ischemia in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"     \"Amniotic fluid embolism syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors for stroke in pregnancy also include the risk factors for nonpregnant patients, such as hypertension, smoking, arterial disease, certain types of heart disease, hyperlipidemia, thrombophilia, infection, paradoxical emboli, and substance abuse. Age over 35, migraine with aura, and black race are additional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/2\">",
"     2",
"    </a>",
"    ]. Mothers with sickle cell disease are also at increased risk for thromboembolic events, including acute stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20458?source=see_link&amp;anchor=H18429428#H18429428\">",
"     \"Pregnancy in women with sickle cell disease\", section on 'SCD course during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors are similar for pregnancy-related intracerebral hemorrhage. In a study that examined a 10-year representative sample of the entire United States obstetrical population, involving nearly seven million deliveries, 423 women had pregnancy-related intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/8\">",
"     8",
"    </a>",
"    ]. Independent risk factors for intracerebral hemorrhage in this population were advanced maternal age, black race, preexisting and gestational hypertension,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    preexisting hypertension superimposed on",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    coagulopathy, and tobacco abuse.",
"   </p>",
"   <p>",
"    The risk of stroke in women with",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Indications for antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All types of stroke can be seen in pregnancy and the puerperium (",
"    <a class=\"graphic graphic_table graphicRef60303 \" href=\"UTD.htm?5/44/5836\">",
"     table 1",
"    </a>",
"    ). However, the major causes are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhagic stroke from aneurysms, arteriovenous malformations, and",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia",
"      </span>",
"     </li>",
"     <li>",
"      Ischemic stroke from cerebral venous sinus thrombosis,",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia,",
"      </span>",
"      and cardioembolism related to valvular heart disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In pregnant patients, ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and cerebral venous thrombosis have clinical features similar to those occurring in nonpregnant patients. In contrast, the syndromes of preeclampsia, eclampsia, and HELLP (hemolysis, elevated liver enzymes, and low platelets) are unique to pregnancy and the postpartum period. There are also several rare causes of stroke that are seen exclusively or predominantly in pregnancy and the puerperium such as trophoblastic embolism, amniotic fluid embolism, and air embolism.",
"   </p>",
"   <p>",
"    Changes in cardiovascular hemodynamics, coagulation factors, hemoconcentration, endothelial dysfunction and inflammation, and impaired cerebrovascular tone (eg,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    reversible posterior leukoencephalopathy syndrome) are some of the important physiologic and pathophysiologic changes that render pregnant women to be at increased risk for",
"    <span class=\"nowrap\">",
"     ischemic/thrombotic",
"    </span>",
"    and hemorrhagic strokes.",
"   </p>",
"   <p>",
"    Etiologies with particular relevance to pregnancy are briefly reviewed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preeclampsia, eclampsia, and HELLP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndromes of severe preeclampsia, eclampsia, and HELLP (hemolysis, elevated liver enzymes, and low platelets) are among the most common causes of both ischemic and hemorrhagic stroke in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/5,6,18,19\">",
"     5,6,18,19",
"    </a>",
"    ]. However, the most frequent cerebrovascular disturbance associated with preeclampsia, eclampsia, and HELLP syndrome is a reversible encephalopathy that is similar if not identical to that which occurs in hypertensive encephalopathy and reversible posterior leukoencephalopathy syndrome. The presumed mechanism is impairment of cerebrovascular autoregulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic manifestations of the reversible encephalopathy associated with severe preeclampsia, eclampsia, and HELLP syndrome may include headache, blurred vision, scotomata, cortical blindness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    generalized tonic-clonic seizures. Untreated cases may progress to coma. Neuroimaging often shows vasogenic edema in subcortical white matter, predominantly in the parietal and occipital lobes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link\">",
"     \"Eclampsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available data regarding ischemic and hemorrhagic stroke associated with severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia/HELLP",
"    </span>",
"    are limited to retrospective studies with small numbers of patients. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from Mexico of 240 women with pregnancy-related cerebrovascular complications,",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia",
"      </span>",
"      was commonly associated with both ischemic stroke of arterial origin (23 of 64 cases [36 percent]) and intracerebral hemorrhage (22 of 40 cases [55 percent]) but less frequently with cerebral venous thrombosis (13 of 136 cases [10 percent]) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review from Maryland of 31 pregnancy-related strokes, the major causes of cerebral infarction (n = 17) were severe preeclampsia or eclampsia (n = 4), primary central nervous system vasculopathy (n = 2), and conditions such as carotid dissection and thrombotic thrombocytopenic purpura [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/5\">",
"       5",
"      </a>",
"      ]. No specific cause was identified in six patients. The major causes of intracerebral hemorrhage (n = 14) were arteriovenous malformation (n = 3), severe preeclampsia or eclampsia (n = 2), cocaine use (n = 2), and primary central nervous system vasculopathy (n = 1); no cause was identified in four. Thus, severe",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia",
"      </span>",
"      accounted for 24 percent of infarctions and 14 percent of hemorrhages.",
"     </li>",
"     <li>",
"      In a study from France of 31 pregnancy-related strokes, eclampsia accounted for 47 percent of infarctions and 44 percent of hemorrhages [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical characteristics of patients with stroke in association with severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia/HELLP",
"    </span>",
"    were illustrated in a review of 28 such patients with a mean age of 30 years (range 14 to 42 years) who were otherwise free of risk factors for stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/18\">",
"     18",
"    </a>",
"    ]. Seven of the patients were ascertained from hospital medical records, while the other 21 were derived from forensic sources. Major findings from this retrospective series were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 27 patients who had intracranial imaging, the type of stroke was hemorrhagic-arterial in 25 (93 percent) and thrombotic-arterial in 2 (7 percent)",
"     </li>",
"     <li>",
"      There were more strokes in the postpartum than antepartum period (16 versus 12 [57 versus 43 percent])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the majority of the cases reported were derived from forensic sources, these findings may not be representative of the risks to the overall population of pregnant women with severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia/HELLP",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preeclampsia, eclampsia, and HELLP syndrome are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link\">",
"     \"Eclampsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1853010\">",
"    <span class=\"h2\">",
"     Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are acute syndromes with abnormalities in multiple organ systems that demonstrate microangiopathic hemolytic anemia and thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"UTD.htm?4/25/4508\">",
"     table 2",
"    </a>",
"    ). Although some studies distinguish between TTP and HUS, the presenting features are similar in most patients: thrombocytopenia and microangiopathic hemolytic anemia without another apparent cause and, in many patients, neurologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal abnormalities. Neurologic manifestations can include coma, confusion, seizure, transient ischemic attack, stroke, reversible posterior leukoencephalopathy syndrome, and headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H112795182#H112795182\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When developing during or after pregnancy, TTP-HUS must be distinguished from severe preeclampsia and the HELLP syndrome, which can be accompanied by acute thrombocytopenic disorders that are expected to resolve spontaneously within several days after delivery. The distinction between TTP-HUS and severe preeclampsia or HELLP is important for therapeutic and prognostic reasons. However, the clinical and histologic features are so similar that establishing the correct diagnosis is often difficult; furthermore, these disorders may occur concurrently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postpartum angiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum angiopathy appears to be one member of a group of reversible cerebral vasoconstriction syndromes (RCVS) with similar clinical and radiologic features that are characterized by thunderclap headache and diffuse, segmental, reversible cerebral vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/20\">",
"     20",
"    </a>",
"    ]. Other entities encompassed by RCVS include idiopathic thunderclap headache with vasospasm, benign angiopathy of the central nervous system, migrainous vasospasm, Call-Fleming syndrome, and drug-induced cerebral vasoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link&amp;anchor=H13#H13\">",
"     \"Thunderclap headache\", section on 'Reversible cerebral vasoconstriction syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpartum angiopathy usually presents with severe headache and neurologic findings that can include visual disturbance, hemiplegia, dysarthria, aphasia, numbness, ataxia, seizure, and encephalopathy, often in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21\">",
"     21",
"    </a>",
"    ]. Vasogenic brain edema, intraparenchymal hemorrhage, subarachnoid hemorrhage, ischemic stroke (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77149 \" href=\"UTD.htm?7/51/7991\">",
"     image 1",
"    </a>",
"    ) and even death have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Blood pressure may be normal or elevated. Smooth narrowing of multiple segments of intracranial arteries is seen on cerebral angiography and can be seen on magnetic resonance angiography or computed tomographic angiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64318 \" href=\"UTD.htm?17/27/17845\">",
"     image 2",
"    </a>",
"    ), although these noninvasive studies may not be able to adequately image smaller arterioles that are typically involved. In addition, cerebral angiography may be normal early in the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21\">",
"     21",
"    </a>",
"    ]. The angiographic changes are reversible, but may persist for days to months.",
"   </p>",
"   <p>",
"    Laboratory testing is usually normal. Cerebrospinal fluid findings are typically without abnormalities, but may show cells and elevated protein, especially if the test is done long after the onset of the clinical findings. It is important to determine if any drugs capable of causing vascular spasm have been used. Some reports suggest that sympathomimetic drugs may increase the risk of postpartum angiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available retrospective studies are inconsistent regarding the frequency of preceding pregnancy complications (eg, eclampsia or gestational diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. However, the clinical, laboratory, and neuroimaging features of postpartum angiopathy and eclampsia are not strictly separated, suggesting these entities may represent different clinical expressions of the same underlying pregnancy-related disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In one retrospective series that reported 18 patients with postpartum angiopathy from three tertiary care centers, pregnancy was complicated by preeclampsia or eclampsia in 7 (39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of postpartum angiopathy and RCVS includes isolated or primary angiitis of the central nervous system. Findings that favor vasculitis rather than this noninflammatory vasculopathy associated with pregnancy include an insidious onset of dull headache, stepwise addition of findings, spinal fluid abnormalities, and more distal intracranial blood vessels affected on angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cerebral venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral venous thrombosis is rare, but occurs more commonly in association with pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/26\">",
"     26",
"    </a>",
"    ]. It presents most often in the immediate postpartum period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In hospital discharge data from the United States covering 2850 pregnancies that included a diagnosis of stroke for the years 2000 and 2001, cerebral venous thrombosis was the cause of 2 percent of pregnancy-related stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/2\">",
"     2",
"    </a>",
"    ]. Smaller retrospective studies have reported that CVT accounts for 3 to 57 percent of pregnancy-related stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/5,19,26-29\">",
"     5,19,26-29",
"    </a>",
"    ]. Some cases have been linked to thrombophilias, inherited and acquired [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Other risk factors include cesarean delivery, hypertension, and infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations consist of headache, vomiting, focal or generalized seizure, confusion, blurred vision, focal neurologic deficits, and altered consciousness. The headache frequently precedes other symptoms, is diffuse, and often severe. The severity of symptoms correlates with the degree of thrombosis and the vessel involved. The diagnosis is confirmed by magnetic resonance imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Clinical aspects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2962251\">",
"    <span class=\"h2\">",
"     Hypercoagulable state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is a hypercoagulable state that is due, in part, to the progressive increase in resistance to activated protein C in the second and third trimesters, as well as decreased protein S activity, increased fibrinogen, increased factors II, VII, VIII, X, XII, and von Willebrand factor, and increased activity of fibrinolytic inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=see_link&amp;anchor=H11#H11\">",
"     \"Hematologic changes in pregnancy\", section on 'Coagulation factors and inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of thrombosis is increased in women with the antiphospholipid syndrome or an inherited thrombophilia, such as factor V Leiden, the prothrombin gene mutation, or a deficiency of antithrombin III, protein C, or protein S. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these abnormalities typically cause venous thrombosis, we suggest a laboratory evaluation for an inherited or acquired thrombophilia for a woman presenting with a nonhemorrhagic ischemic neurologic event during pregnancy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnostic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation and treatment of stroke in pregnant women is similar to that in nonpregnant individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An imaging study of the brain is an essential component of the evaluation, regardless of cause. Noncontrast head CT is typically the first diagnostic study in patients with suspected stroke. The main advantages of CT are widespread access and speed of acquisition. However, MRI is safe during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .) In addition, MRI may be more sensitive than CT for the detection of small infarcts, and MRI with diffusion-weighted sequences is superior to CT for the diagnosis of early infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H10#H10\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neuroradiographic abnormalities of reversible posterior leukoencephalopathy syndrome are often apparent on head CT but are best depicted by MRI using fluid-attenuated inversion recovery (FLAIR) sequences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link&amp;anchor=H15#H15\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iodine and gadolinium-based contrast agents are avoided in pregnancy, if possible, and the abdomen should be shielded from radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small subarachnoid hemorrhage (SAH) can be missed by both CT and MRI, especially as the time from SAH onset to imaging study increases. Lumbar puncture may be needed to make the diagnosis of SAH in such patients. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation exposure to the fetus with head CT, cerebral angiography, and chest x-ray is approximately 50, 10, and 1 mrad, respectively. These levels are considered safe, as there is",
"    <strong>",
"     no",
"    </strong>",
"    evidence of an increased risk of fetal anomalies, intellectual disability, growth restriction, or pregnancy loss from ionizing radiation at doses less than 5000 mrad. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Effects of ionizing radiation on the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography and carotid Doppler studies may be useful if clinical findings point to cardiac or carotid pathology. Additional laboratory evaluation includes electrocardiogram, complete blood count, metabolic profile, peripheral blood smear, HIV testing, urine drug screen, and antinuclear antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest a laboratory evaluation for an inherited or acquired thrombophilia for woman presenting with a cryptogenic ischemic stroke or TIA during pregnancy. Although data are limited, the potential value of this approach was illustrated in a report of 12 previously healthy women who had a first transient ischemic neurologic event during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/31\">",
"     31",
"    </a>",
"    ]. Ten (83 percent) had an inherited thrombophilia, much higher than the 17 percent rate seen in 24 controls. (See",
"    <a class=\"local\" href=\"#H2962251\">",
"     'Hypercoagulable state'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MECHANISM-SPECIFIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of stroke during pregnancy is guided by the stroke etiology and subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, some unique considerations in pregnant women with acute ischemic stroke. For one, pregnancy has been considered by some experts to be a relative contraindication to the use of thrombolytic treatment for acute stroke. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Fibrinolytic (thrombolytic) therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another issue is that some women with ischemic stroke associated with hypercoagulable states or cerebral venous thrombosis will require anticoagulation throughout the pregnancy and during the immediate postpartum period. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Anticoagulation during pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of preeclampsia, eclampsia, and HELLP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of management of severe preeclampsia and eclampsia are to stabilize the mother, prevent recurrent convulsions, treat severe hypertension to reduce or prevent cerebral edema and hemorrhage, and initiate prompt delivery.",
"   </p>",
"   <p>",
"    We suggest antihypertensive therapy for adult pregnant women at systolic pressures &ge;150 mmHg and diastolic blood pressures &ge;100 mmHg. We initiate treatment at a lower threshold in younger women whose baseline blood pressure is low, and in those with symptoms that may be attributable to elevated blood pressure (eg, headache, visual disturbances, chest discomfort). Indications for antihypertensive therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Indications for antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is the drug of choice for the prevention of recurrent eclamptic seizures. Platelet transfusion is indicated in the HELLP syndrome if there is significant maternal bleeding or if the platelet count is &lt;20,000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H9#H9\">",
"     \"Eclampsia\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link&amp;anchor=H10#H10\">",
"     \"HELLP syndrome\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1853037\">",
"    <span class=\"h2\">",
"     Treatment of TTP-HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange is the treatment of choice for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) occurring during pregnancy. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H41#H41\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of postpartum angiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all of the central nervous system vasculopathy syndromes, there is no proof that any therapeutic intervention is effective for postpartum angiopathy. The syndrome is usually self-limiting. Some patients have received glucocorticoids (especially those with findings that suggest possible isolated central nervous system vasculitis), calcium channel blockers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnesium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21\">",
"     21",
"    </a>",
"    ]. Progressive deterioration is usually a relatively early finding (within the first few weeks) and may be due to increasing brain edema.",
"   </p>",
"   <p>",
"    The prognosis of postpartum angiopathy was thought to be good, but in one of the largest series (n = 18), a complete recovery was achieved by nine patients (50 percent), while a fulminant course followed by death affected four patients (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/21\">",
"     21",
"    </a>",
"    ]. There is no evidence of a high risk of recurrence in future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/33\">",
"     33",
"    </a>",
"    ], although at least one recurrent case has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/34\">",
"     34",
"    </a>",
"    ], or of an increased risk of",
"    <span class=\"nowrap\">",
"     eclampsia/preeclampsia",
"    </span>",
"    in future pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute ischemic stroke in pregnancy is mostly guided by the same principles as in the general population. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is recommended for patients with acute ischemic stroke who are not receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , or oral anticoagulants. This recommendation is in accord with current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Aspirin should be given within 48 hours of stroke onset and may also be used in combination with subcutaneous heparin for deep vein thrombosis prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link&amp;anchor=H3#H3\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombotic strokes associated with hypercoagulable states are generally treated by anticoagulation (to prevent recurrence) and possibly by acute thrombolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fibrinolytic (thrombolytic) therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the fibrinolytic agents, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue plasminogen activator) is approved for use in acute stroke. Treatment with intravenous alteplase is beneficial in selected patients (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 3",
"    </a>",
"    ) with acute ischemic stroke who can be treated within 4.5 hours of symptom onset. Issues related to such therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy and safety of thrombolytic therapy for acute ischemic stroke in pregnant women are unknown. There are no randomized trials or large observational studies evaluating such therapy. The available reports have either included a small number of patients or have evaluated thrombolytic therapy in pregnant patients for indications not limited to acute ischemic stroke. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of off-label thrombolysis for acute ischemic stroke identified 11 pregnant women who were treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (n = 6) or intraarterial thrombolysis (n = 5) using alteplase or urokinase. Symptomatic intracranial hemorrhage occurred in 1 of the 11 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another review of 172 pregnant women treated with thrombolytics for various thromboembolic conditions found that the rate of overall maternal hemorrhagic complications was 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    does not cross the placenta but is considered pregnancy category C (ie, risk cannot be ruled out (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 4",
"    </a>",
"    )). There are no data regarding teratogenicity in humans, but no such risk was found in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are concerns regarding the maternal and fetal risk of hemorrhagic complications with thrombolysis, possibly resulting in premature labor, placental abruption,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/38,40\">",
"     38,40",
"    </a>",
"    ]. Hemorrhage during parturition or cesarean delivery is a particular risk with fibrinolytic therapy if the patient goes into labor or operative delivery is required [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, some experts have considered pregnancy to be a relative contraindication to the use of thrombolysis for acute stroke in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other experts believe that thrombolytic therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be withheld in pregnant patients when otherwise indicated to treat life-threatening or potentially debilitating thromboembolic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]. The 2013 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association guidelines consider pregnancy as one of several relative exclusions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    therapy, stating that under some circumstances &ndash; with careful consideration and weighting of risk-to-benefit &ndash; patients may receive fibrinolytic therapy despite one or more relative contraindications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/36\">",
"     36",
"    </a>",
"    ]. Similarly, the package insert for alteplase does not list pregnancy as an exclusion criterion but states that the risk of therapy may be increased in pregnancy and that alteplase should be used in pregnancy only if the potential benefit outweighs the potential risk to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    can be given in pregnancy after careful discussion of the potential risks and benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/42\">",
"     42",
"    </a>",
"    ]. We suggest intravenous alteplase therapy for otherwise eligible pregnant women with acute ischemic stroke provided that treatment is initiated within 4.5 hours of clearly defined symptom onset (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 3",
"    </a>",
"    ). Eligible patients should be treated as quickly as possible within the appropriate 3 or 4.5 hour time limit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another option is intra-arterial thrombolytic therapy, which some experts believe can minimize the risk of decidual hemorrhage (ie, abruption), a cause of perinatal mortality. Intra-arterial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for acute ischemic stroke should be attempted only at centers with appropriate expertise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H24#H24\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intra-arterial thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary prevention of ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;An antiplatelet agent for secondary prevention is recommended for patients with a history of noncardioembolic stroke or transient ischemic attack (TIA) of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    are all acceptable options for preventing recurrent noncardioembolic ischemic stroke. An aspirin dose of 60 to 81",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is considered safe in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Clopidogrel (pregnancy category B) and the combination of aspirin-extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (pregnancy category D) (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 4",
"    </a>",
"    ) have not been evaluated in large numbers of patients or over prolonged periods of time.",
"   </p>",
"   <p>",
"    Anticoagulants and antiplatelet agents have been employed to prevent stroke due to the antiphospholipid syndrome. Pregnant women with the antiphospholipid syndrome are at increased risk for maternal thrombosis and for late fetal loss, early and severe preeclampsia, growth restriction, and, possibly, recurrent early pregnancy loss. The management of these women is controversial and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=see_link\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines recommend that patients with ischemic stroke or TIA who have an established inherited thrombophilia should be evaluated for deep vein thrombosis, which is an indication for short- or long-term anticoagulation, depending on the clinical and hematologic circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/46\">",
"     46",
"    </a>",
"    ]. In the absence of venous thrombosis, either long-term anticoagulation or antiplatelet therapy is considered reasonable. Patients with a history of recurrent thrombotic events may be considered for long-term anticoagulation.",
"   </p>",
"   <p>",
"    The evaluation and management of the inherited thrombophilias is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cerebral venous sinus thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay for the treatment of symptomatic cerebral venous sinus thrombosis, with or without hemorrhagic venous infarction, is anticoagulation therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous LMW heparin. For women with cerebral venous thrombosis during pregnancy, guidelines published in 2011 from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association conclude that low molecular weight heparin in full anticoagulant doses should be continued throughout pregnancy, and low molecular weight heparin or a vitamin K antagonist with a target INR of 2 to 3 should be continued for at least six weeks postpartum for a total minimum duration of therapy of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/47\">",
"     47",
"    </a>",
"    ]. Symptomatic management issues include control of seizures and intracranial hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intracerebral hemorrhage during pregnancy or the postpartum period is most often caused by aneurysmal rupture or bleeding from a vascular malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Preeclampsia/eclampsia/HELLP",
"    </span>",
"    is another important cause of hemorrhagic strokes during pregnancy.",
"   </p>",
"   <p>",
"    One retrospective study reported 154 women with intracranial hemorrhage during pregnancy or the puerperium who had an identified vascular lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/48\">",
"     48",
"    </a>",
"    ]. The cause of the hemorrhage was cerebral aneurysm or arteriovenous malformation in 77 and 23 percent, respectively. Aneurysm rupture during pregnancy occurred most frequently in the third trimester (55 percent), and less so in the second trimester (31 percent), first trimester (6 percent), or postpartum period (8 percent). Hemodynamic, angiogenic, and endocrine changes associated with pregnancy may affect the growth and rupture of aneurysms in the gravid patient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/49\">",
"     49",
"    </a>",
"    ]. However, there is conflicting evidence regarding whether the risk of aneurysmal subarachnoid hemorrhage is increased with pregnancy and the puerperium (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    One old retrospective study found that among 37 pregnant women in good condition after subarachnoid hemorrhage from a verified intracranial aneurysm, recurrent bleeding during the same pregnancy from surgically untreated aneurysms occurred in 13 (35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/50\">",
"     50",
"    </a>",
"    ]. The overall incidence of rebleeding after initial SAH in the modern era is uncertain. Limited data from older literature suggest that the maternal case fatality rate of aneurysmal subarachnoid hemorrhage is approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/48\">",
"     48",
"    </a>",
"    ], which is similar to that of the general population (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Complications'",
"    </a>",
"    ). The fetal case fatality rate is approximately 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracerebral aneurysms and arteriovenous malformations can be managed by surgical (ie, clipping) or endovascular (eg, embolization) treatment of the causative lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, ruptured intracranial aneurysms in pregnant women are treated as they would be in patients who are not pregnant. Endovascular coiling is preferred to surgical clipping for appropriately shaped aneurysms. A number of reports have described successful endovascular coiling of intracranial aneurysms associated with term or near-term births [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. However, aneurysms with broad necks, a low neck-to-fundus ratio, distal segment lesions, and a number of giant aneurysms are not amenable to endovascular therapy. Stable, unruptured asymptomatic aneurysms can usually be observed without intervention during pregnancy, whereas symptomatic or enlarging unruptured aneurysms can be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/3,56\">",
"     3,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, symptomatic arteriovenous malformations in pregnant women are treated as they would be in patients who are not pregnant. There are a few case reports of successful embolization of hemorrhagic arteriovenous malformations during pregnancy via the endovascular approach, followed by surgical resection of the AVM [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. CT angiography with shielding of the abdomen during pregnancy can be performed prior to the embolization procedure to delineate any pre-nidal or intra-nidal aneurysms that might be the source of the bleed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"     \"Brain arteriovenous malformations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As noted above, retrospective data suggest that severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia/HELLP",
"    </span>",
"    is the cause of 14 to 55 percent of hemorrhagic strokes in pregnancy. In such cases, management goals are to stabilize the mother, prevent recurrent convulsions, treat severe hypertension to reduce or prevent cerebral edema and hemorrhage, and initiate delivery of the fetus. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment of preeclampsia, eclampsia, and HELLP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have had the cause of their cerebral hemorrhage treated (eg, clipping or embolization of a cerebral aneurysm or arteriovenous malformation) may undergo labor and delivery. However, there is considerable controversy regarding management of labor and delivery with ruptured aneurysms or arteriovenous malformations that have not been definitively treated. The two major alternatives are (1) prophylactic cesarean delivery and (2) regional anesthesia with instrumental delivery to eliminate cerebral hemodynamic fluctuations associated with pain and the Valsalva maneuver.",
"   </p>",
"   <p>",
"    There are no data from large series or randomized trials, but it appears that maternal and fetal mortality rates are the same with both methods. As a result, cesarean delivery should be reserved for the usual obstetrical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/48\">",
"     48",
"    </a>",
"    ]. Aneurysm rupture has occurred during elective cesarean birth; thus it is not completely protective. Therefore, regardless of the mode of delivery, it is important to control hypertension and minimize fluctuations in blood pressure.",
"   </p>",
"   <p>",
"    Some experts believe that selected patients who are stable after intracranial hemorrhage can be managed supportively until the pregnancy is taken to term [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/51\">",
"     51",
"    </a>",
"    ]. The lesion can then be treated by surgical or endovascular means after delivery. However, emergency surgery is indicated if there is neurologic deterioration caused by recurrent bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anticoagulation during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to anticoagulation in pregnant women, including recommendations from the American College of Chest Physicians (ACCP) regarding appropriate anticoagulation regimens, are briefly reviewed here and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive recommendations for anticoagulant therapy for stroke during pregnancy are difficult because of a lack of critical studies. In theory, anticoagulation can be given to prevent recurrent thrombosis in hypercoagulable states and to treat cerebral venous thrombosis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Secondary prevention of ischemic stroke'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Cerebral venous sinus thrombosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While there are no randomized controlled trials or epidemiologic studies to guide the duration of anticoagulant therapy, many patients will require anticoagulation throughout the pregnancy and during the immediate postpartum period, after which re-evaluation of the need for treatment can take place.",
"   </p>",
"   <p>",
"    The 2012 ACCP guidelines recommend low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) instead of unfractionated heparin for the prevention and treatment of venous thromboembolism during pregnancy, and recommend LMWH instead of vitamin K antagonist treatment antenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/59\">",
"     59",
"    </a>",
"    ]. The ACCP guidelines further suggest that anticoagulant therapy be continued for at least six weeks postpartum, and for a minimum total duration of three months, for pregnant women with acute venous thromboembolism.",
"   </p>",
"   <p>",
"    The ACCP guidelines recommend discontinuation of LMWH or unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    at least 24 hours before induction of labor, cesarean section, or expected time of neuraxial anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/59\">",
"     59",
"    </a>",
"    ]. Other approaches to the management of anticoagulation and neuraxial analgesia are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12561180#H12561180\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Neuraxial analgesia and the anticoagulated patient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns related to the different types of anticoagulants can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      is potentially teratogenic when given between the sixth and ninth weeks of gestation. In addition, when given in the second and third trimesters, warfarin can lead to central nervous system abnormalities that are thought to be due to repeated cerebral microhemorrhages.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      does not cross the placenta and therefore is not teratogenic and does not anticoagulate the fetus. Concerns with heparin therapy include the relative difficulty of maintaining a stable therapeutic response, the inconvenience of parenteral administration, and the complications of heparin-induced thrombocytopenia and bone demineralization, which can lead to fractures in patients treated for more than six months.",
"     </li>",
"     <li>",
"      Low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      does not cross the placenta and, compared to unfractionated heparin, has the advantages of producing a more predictable anticoagulant response to fixed doses administered once or twice daily and is less likely to produce thrombocytopenia or, possibly, bone demineralization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stroke remote from term",
"    </span>",
"    &nbsp;&mdash;&nbsp;When stroke occurs in a pregnant woman who is &lt;24 weeks of gestation, the stroke should be managed as dictated by the patient's clinical condition. Every effort should be made to protect the salvageable brain tissue, prevent medical complications (eg, aspiration), control maternal physiologic factors that may worsen the stroke, such as blood pressure, and facilitate long term physical rehabilitation. Pregnancy termination is an option if thrombolytic therapy is being considered.",
"   </p>",
"   <p>",
"    As mentioned earlier, some women with ischemic stroke or cerebral venous sinus thrombosis will require anticoagulation throughout the pregnancy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Anticoagulation during pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Stroke near term",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have a stroke between 24 and 32 weeks gestation, antenatal glucocorticoids can be administered to accelerate fetal lung maturation. A multidisciplinary approach in consultation with neurology, neurosurgery, anesthesia, neonatology, and perinatology should take place to stabilize the mother and assess fetal status. As long as maternal and fetal well-being are not deteriorating, plans can be made to continue the pregnancy with a scheduled controlled delivery between 34 to 39 weeks gestation to optimize fetal outcome.",
"   </p>",
"   <p>",
"    For pregnant women diagnosed with ischemic stroke or cerebral venous sinus thrombosis, anticoagulation with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparin (LMWH), or antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be considered in consultation with neurologists throughout the remainder of the pregnancy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Anticoagulation during pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    After 36 weeks of pregnancy, LMWH can be changed over to unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    until a scheduled labor induction at 39 weeks can take place, and LMWH can resume in the postpartum period.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be stopped within one or two weeks of a planned delivery; ie, induction of labor or cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small fraction of iodinated or gadolinium contrast agents is secreted in maternal milk. Based upon these data, women who require neurovascular imaging should discontinue breast-feeding for 24 hours after receiving intravenous contrast media and discard milk expressed during that interval before resuming normal breastfeeding.",
"   </p>",
"   <p>",
"    There are no contraindications to breastfeeding while being treated with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin. Similarly, nursing mothers can safely take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    because there is no convincing evidence that warfarin exerts an anticoagulant effect on the breast-fed infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FUTURE PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When counseling women with a prior history of stroke, it is important to obtain a detailed history of the etiology of and the circumstances surrounding the stroke to determine the stroke type &mdash;",
"    <span class=\"nowrap\">",
"     ischemic/thrombotic",
"    </span>",
"    or hemorrhagic &mdash; and underlying mechanism. This classification will help to guide management for the impending pregnancy. Consultation with a neurologist, hematologist, or neurosurgeon may also be indicated prior to attempting conception to optimize pregnancy outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Stroke risk in future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most women with prior stroke during pregnancy, the recurrence rate during a subsequent pregnancy and postpartum period is low (&le;1 percent), particularly if any causative vascular lesions have been repaired [",
"    <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/30,60,61\">",
"     30,60,61",
"    </a>",
"    ]. However, data are sparse, and the risk in future pregnancies varies depending upon the cause of the initial stroke.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of recurrent ischemic stroke is low. This was illustrated in a review of 441 women with a history of ischemic stroke (373 with arterial ischemic stroke and 68 with cerebral venous thrombosis); during a mean follow-up of five years, there were 13 recurrent arterial ischemic strokes and no recurrences of cerebral venous thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/60\">",
"       60",
"      </a>",
"      ]. The overall risk of recurrence was 1 percent at one year and 2.3 percent at five years. The risk of recurrence during pregnancy or the puerperium was 1.8 percent (not significantly different from outside pregnancy), but the relative risk of recurrence was significantly higher during the postpartum period (risk ratio 9.7, 95 % CI 1.2-78.9). The outcome of the 187 subsequent pregnancies was similar to that expected from the general population. The authors concluded that a previous ischemic stroke is not a contraindication to a subsequent pregnancy.",
"      <br/>",
"      <br/>",
"      After addressing any underlying medical disorders, low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      can be considered in women with prior history of",
"      <span class=\"nowrap\">",
"       ischemic/thrombotic",
"      </span>",
"      stroke for empiric prophylaxis against future thrombotic stroke during future pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Few studies have examined recurrence after pregnancy-related stroke associated with hypercoagulable states. The largest evaluated 12 women with a previous cerebrovascular event (infarction, TIA, or amaurosis fugax) in the setting of thrombophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/62\">",
"       62",
"      </a>",
"      ]. In 15 subsequent pregnancies, there were four thromboembolic events, including two amaurosis fugax, one TIA, and one cerebral infarction. None of the patients had persistent neurologic deficits.",
"     </li>",
"     <li>",
"      There are insufficient data to assess the risk of recurrent cerebral venous sinus thrombosis (CVT), and the role of antithrombotic prophylaxis during subsequent pregnancies is unproven in women with a history of CVT. There is no consensus regarding this issue. Many experts believe that antithrombotic prophylaxis during pregnancy is probably unnecessary unless a prothrombotic condition or a previous thromboembolism (ie, a previous CVT or deep venous thrombosis before the index CVT) has been identified. However, other experts would prefer to treat with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or subcutaneous low molecular weight heparin during the late third trimester",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      up to eight weeks postpartum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link&amp;anchor=H21#H21\">",
"       \"Treatment and prognosis of cerebral venous thrombosis\", section on 'Subsequent pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Untreated vascular malformations are prone to rebleeding whether or not the patient becomes pregnant. In one study, the annual rate of recurrent hemorrhage in women with a brain arteriovenous malformation was estimated to be 31 percent in the first year following an initial hemorrhage and 6 percent in subsequent years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/56/24458/abstract/63\">",
"       63",
"      </a>",
"      ]. Therefore, vascular malformations should be definitively treated by surgical excision or endovascular embolization in women before reattempting pregnancy, if possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"       \"Vascular malformations of the central nervous system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link&amp;anchor=H11#H11\">",
"       \"Brain arteriovenous malformations\", section on 'Risk during pregnancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stroke is more common in pregnant women, especially in the puerperium. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Preeclampsia/eclampsia",
"      </span>",
"      is one of the most common causes of both ischemic infarction and hemorrhagic stroke in pregnancy. Other causes are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef60303 \" href=\"UTD.htm?5/44/5836\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation and treatment of stroke in pregnant women is similar to that in nonpregnant individuals. A head CT scan is usually the first imaging modality obtained because it is both informative and readily available. However, brain MRI is more sensitive than CT for the detection of small infarcts and for visualization of very early infarction when diffusion-weighted imaging is employed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of stroke during pregnancy is guided by the stroke etiology and subtype. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mechanism-specific treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia/HELLP,",
"      </span>",
"      the goals are to stabilize the mother, prevent recurrent convulsions, treat severe hypertension to reduce or prevent cerebral edema and hemorrhage, and initiate prompt delivery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment of preeclampsia, eclampsia, and HELLP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy is recommended for patients with acute ischemic stroke who are not receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      or anticoagulants. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Acute ischemic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An antiplatelet agent for secondary prevention is recommended for patients with a history of noncardioembolic stroke or transient ischemic attack (TIA) of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Secondary prevention of ischemic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of symptomatic cerebral venous sinus thrombosis, with or without hemorrhagic venous infarction, is anticoagulation therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cerebral venous sinus thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subarachnoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intracerebral hemorrhage due to aneurysmal rupture or bleeding from a vascular malformation can be managed by surgical (ie, clipping) or endovascular (eg, embolization) treatment of the causative lesion. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of recurrent stroke in future pregnancy is probably low, but data are sparse. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Stroke risk in future pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/1\">",
"      Petitti DB, Sidney S, Quesenberry CP Jr, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/2\">",
"      James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/3\">",
"      Davie CA, O'Brien P. Stroke and pregnancy. J Neurol Neurosurg Psychiatry 2008; 79:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/4\">",
"      Scott CA, Bewley S, Rudd A, et al. Incidence, risk factors, management, and outcomes of stroke in pregnancy. Obstet Gynecol 2012; 120:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/5\">",
"      Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/6\">",
"      Sharshar T, Lamy C, Mas JL. Incidence and causes of strokes associated with pregnancy and puerperium. A study in public hospitals of Ile de France. Stroke in Pregnancy Study Group. Stroke 1995; 26:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/7\">",
"      Grosset DG, Ebrahim S, Bone I, Warlow C. Stroke in pregnancy and the puerperium: what magnitude of risk? J Neurol Neurosurg Psychiatry 1995; 58:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/8\">",
"      Bateman BT, Schumacher HC, Bushnell CD, et al. Intracerebral hemorrhage in pregnancy: frequency, risk factors, and outcome. Neurology 2006; 67:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/9\">",
"      Lanska DJ, Kryscio RJ. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000; 31:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/10\">",
"      Fox MW, Harms RW, Davis DH. Selected neurologic complications of pregnancy. Mayo Clin Proc 1990; 65:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/11\">",
"      Salonen Ros H, Lichtenstein P, Bellocco R, et al. Increased risks of circulatory diseases in late pregnancy and puerperium. Epidemiology 2001; 12:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/12\">",
"      Tiel Groenestege AT, Rinkel GJ, van der Bom JG, et al. The risk of aneurysmal subarachnoid hemorrhage during pregnancy, delivery, and the puerperium in the Utrecht population: case-crossover study and standardized incidence ratio estimation. Stroke 2009; 40:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/13\">",
"      Brown RD Jr, Flemming KD, Meyer FB, et al. Natural history, evaluation, and management of intracranial vascular malformations. Mayo Clin Proc 2005; 80:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/14\">",
"      Horton JC, Chambers WA, Lyons SL, et al. Pregnancy and the risk of hemorrhage from cerebral arteriovenous malformations. Neurosurgery 1990; 27:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/15\">",
"      Ros HS, Lichtenstein P, Bellocco R, et al. Pulmonary embolism and stroke in relation to pregnancy: how can high-risk women be identified? Am J Obstet Gynecol 2002; 186:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/16\">",
"      Mas JL, Lamy C. Stroke in pregnancy and the puerperium. J Neurol 1998; 245:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/17\">",
"      Feske SK. Stroke in pregnancy. Semin Neurol 2007; 27:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/18\">",
"      Martin JN Jr, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/19\">",
"      Cantu-Brito C, Arauz A, Aburto Y, et al. Cerebrovascular complications during pregnancy and postpartum: clinical and prognosis observations in 240 Hispanic women. Eur J Neurol 2011; 18:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/20\">",
"      Singhal AB, Bernstein RA. Postpartum angiopathy and other cerebral vasoconstriction syndromes. Neurocrit Care 2005; 3:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/21\">",
"      Fugate JE, Ameriso SF, Ortiz G, et al. Variable presentations of postpartum angiopathy. Stroke 2012; 43:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/22\">",
"      Fugate JE, Wijdicks EF, Parisi JE, et al. Fulminant postpartum cerebral vasoconstriction syndrome. Arch Neurol 2012; 69:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/23\">",
"      Bakhru A, Atlas RO. A case of postpartum cerebral angiitis and review of the literature. Arch Gynecol Obstet 2011; 283:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/24\">",
"      Singhal AB. Postpartum angiopathy with reversible posterior leukoencephalopathy. Arch Neurol 2004; 61:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/25\">",
"      Fletcher JJ, Kramer AH, Bleck TP, Solenski NJ. Overlapping features of eclampsia and postpartum angiopathy. Neurocrit Care 2009; 11:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/26\">",
"      Jeng JS, Tang SC, Yip PK. Incidence and etiologies of stroke during pregnancy and puerperium as evidenced in Taiwanese women. Cerebrovasc Dis 2004; 18:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/27\">",
"      Skidmore FM, Williams LS, Fradkin KD, et al. Presentation, etiology, and outcome of stroke in pregnancy and puerperium. J Stroke Cerebrovasc Dis 2001; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/28\">",
"      Witlin AG, Friedman SA, Egerman RS, et al. Cerebrovascular disorders complicating pregnancy--beyond eclampsia. Am J Obstet Gynecol 1997; 176:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/29\">",
"      Liang CC, Chang SD, Lai SL, et al. Stroke complicating pregnancy and the puerperium. Eur J Neurol 2006; 13:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/30\">",
"      Sibai BM, Coppage KH. Diagnosis and management of women with stroke during pregnancy/postpartum. Clin Perinatol 2004; 31:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/31\">",
"      Kupferminc MJ, Yair D, Bornstein NM, et al. Transient focal neurological deficits during pregnancy in carriers of inherited thrombophilia. Stroke 2000; 31:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/32\">",
"      Treadwell SD, Thanvi B, Robinson TG. Stroke in pregnancy and the puerperium. Postgrad Med J 2008; 84:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/33\">",
"      R&eacute;mi J, Pfefferkorn T, Fesl G, et al. Uncomplicated pregnancy and delivery after previous severe postpartum cerebral angiopathy. Case Rep Neurol 2011; 3:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/34\">",
"      Ursell MR, Marras CL, Farb R, et al. Recurrent intracranial hemorrhage due to postpartum cerebral angiopathy: implications for management. Stroke 1998; 29:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/35\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/36\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/37\">",
"      Aleu A, Mellado P, Lichy C, et al. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke 2007; 38:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/38\">",
"      Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995; 50:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/39\">",
"      Leonhardt G, Gaul C, Nietsch HH, et al. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis 2006; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/40\">",
"      Murugappan A, Coplin WM, Al-Sadat AN, et al. Thrombolytic therapy of acute ischemic stroke during pregnancy. Neurology 2006; 66:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/41\">",
"      Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:630S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/42\">",
"      De Keyser J, Gdovinov&aacute; Z, Uyttenboogaart M, et al. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007; 38:2612.",
"     </a>",
"    </li>",
"    <li>",
"     Activase&reg; (Alteplase). Full prescribing information. www.gene.com/gene/products/information/cardiovascular/activase/insert.jsp (Accessed on March 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/44\">",
"      Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993; 329:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/45\">",
"      Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001; 322:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/46\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/47\">",
"      Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/48\">",
"      Dias MS, Sekhar LN. Intracranial hemorrhage from aneurysms and arteriovenous malformations during pregnancy and the puerperium. Neurosurgery 1990; 27:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/49\">",
"      Marshman LA, Aspoas AR, Rai MS, Chawda SJ. The implications of ISAT and ISUIA for the management of cerebral aneurysms during pregnancy. Neurosurg Rev 2007; 30:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/50\">",
"      POOL JL. TREATMENT OF INTRACRANIAL ANEURYSMS DURING PREGNANCY. JAMA 1965; 192:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/51\">",
"      Qaiser R, Black P. Neurosurgery in pregnancy. Semin Neurol 2007; 27:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/52\">",
"      Tarnaris A, Haliasos N, Watkins LD. Endovascular treatment of ruptured intracranial aneurysms during pregnancy: is this the best way forward? Case report and review of the literature. Clin Neurol Neurosurg 2012; 114:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/53\">",
"      Pumar JM, Pardo MI, Carreira JM, et al. Endovascular treatment of an acutely ruptured intracranial aneurysm in pregnancy: report of eight cases. Emerg Radiol 2010; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/54\">",
"      Meyers PM, Halbach VV, Malek AM, et al. Endovascular treatment of cerebral artery aneurysms during pregnancy: report of three cases. AJNR Am J Neuroradiol 2000; 21:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/55\">",
"      Piotin M, de Souza Filho CB, Kothimbakam R, Moret J. Endovascular treatment of acutely ruptured intracranial aneurysms in pregnancy. Am J Obstet Gynecol 2001; 185:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/56\">",
"      Stoodley MA, Macdonald RL, Weir BK. Pregnancy and intracranial aneurysms. Neurosurg Clin N Am 1998; 9:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/57\">",
"      Dashti SR, Spalding AC, Yao TL. Multimodality treatment of a ruptured grade IV posterior fossa arteriovenous malformation in a patient pregnant with twins: case report. J Neurointerv Surg 2012; 4:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/58\">",
"      Jermakowicz WJ, Tomycz LD, Ghiassi M, Singer RJ. Use of endovascular embolization to treat a ruptured arteriovenous malformation in a pregnant woman: a case report. J Med Case Rep 2012; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/59\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/60\">",
"      Lamy C, Hamon JB, Coste J, Mas JL. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. French Study Group on Stroke in Pregnancy. Neurology 2000; 55:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/61\">",
"      Coppage KH, Hinton AC, Moldenhauer J, et al. Maternal and perinatal outcome in women with a history of stroke. Am J Obstet Gynecol 2004; 190:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/62\">",
"      Soriano D, Carp H, Seidman DS, et al. Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events. Acta Obstet Gynecol Scand 2002; 81:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/56/24458/abstract/63\">",
"      Mast H, Young WL, Koennecke HC, et al. Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet 1997; 350:1065.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1108 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24458=[""].join("\n");
var outline_f23_56_24458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preeclampsia, eclampsia, and HELLP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1853010\">",
"      Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postpartum angiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2962251\">",
"      Hypercoagulable state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MECHANISM-SPECIFIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of preeclampsia, eclampsia, and HELLP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1853037\">",
"      Treatment of TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of postpartum angiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fibrinolytic (thrombolytic) therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary prevention of ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cerebral venous sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stroke remote from term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stroke near term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FUTURE PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Stroke risk in future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1108|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/51/7991\" title=\"diagnostic image 1\">",
"      Brain MRI postpartum angiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/27/17845\" title=\"diagnostic image 2\">",
"      CTA segmental narrowing of intracranial vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/44/5836\" title=\"table 1\">",
"      Causes of stroke in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4508\" title=\"table 2\">",
"      Major causes of TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 3\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 4\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=related_link\">",
"      Hematologic changes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20634?source=related_link\">",
"      Neurologic disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20458?source=related_link\">",
"      Pregnancy in women with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_56_24459="Predictors of malignancy in weight loss";
var content_f23_56_24459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of malignancy among patients with unexplained involuntary weight loss",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Predictor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Dichotomized predictor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cut-point",
"       </td>",
"       <td class=\"subtitle2\">",
"        OR (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        &gt;80 years",
"       </td>",
"       <td>",
"        3.4 (1.1-9.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WBC",
"       </td>",
"       <td>",
"        &gt;12K cells/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        3.6 (1.3-10.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin",
"       </td>",
"       <td>",
"        &lt;3.5 g/dL",
"       </td>",
"       <td>",
"        6.7 (3.3-14.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkaline phosphatase",
"       </td>",
"       <td>",
"        &gt;300 U/L",
"       </td>",
"       <td>",
"        11.9 (3.9-36.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate dehydrogenase",
"       </td>",
"       <td>",
"        &gt;500 U/L",
"       </td>",
"       <td>",
"        12.5 (3.9-39.8)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hernandez, JL, Matorras, P, Riancho, JA, Gonz&aacute;lez-Mac&iacute;as, J. Involuntary weight loss without specific symptoms: A clinical prediction score for malignant neoplasm. QJM 2003; 96:649.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24459=[""].join("\n");
var outline_f23_56_24459=null;
var title_f23_56_24460="General screening ECG";
var content_f23_56_24460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for a positive 12-lead ECG",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        P wave",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrial enlargement: negative portion of the P wave in lead V1 &ge;0.1 mV in depth and &ge;0.04 in duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right atrial enlargement: peaked P wave in leads II and III or V1 &ge;0.25 mV in amplitude",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        QRS complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frontal plane axis deviation: right &ge; +120&ordm; or left -30&ordm; to -90&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased voltage: amplitude of R or S wave in a standard lead &ge;2 mV, S wave in lead V1 or V2 &ge;3 mV, or R wave in lead V5 or V6 &ge;3 mV;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal Q waves &ge;0.04 s in duration or &ge;25 percent of the height of the ensuing R wave or QS pattern in two or more leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right or left bundle branch block with QRS duration &ge;0.12 s",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R or R' wave in lead V1 &ge;0.5 mV in amplitude and R/S ratio &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ST-segment, T-waves, and QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST-segment depression or T-wave flattening or inversion in two or more leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolongation of heart rate corrected QT interval &gt;0.44 s in males and &gt;0.46 s in females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rhythm and conduction abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature ventricular beats or more severe ventricular arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supraventricular tachycardias, atrial flutter, or atrial fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short PR interval (&lt;0.12 s) with or without 'delta' wave",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus bradycardia with resting heart rate &le;40 beats/min*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First (PR &ge;0.21 s&bull;), second or third degree atrioventricular block",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Increasing less than 100 beats/min during limited exercise test.",
"     <br>",
"      &bull; Not shortening with hyperventilation or limited exercise test.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516. Copyright &copy;2005 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24460=[""].join("\n");
var outline_f23_56_24460=null;
var title_f23_56_24461="Asthma adherence I";
var content_f23_56_24461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81611%7EPULM%2F56319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81611%7EPULM%2F56319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identifying problems in taking medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Review your medicine record",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Keep a record of when you take your medicines for about a week. In",
"addition to the time of day, write down where you are and what you are",
"doing. After a week, you can review the record and answer the following",
"questions to help you see where you are having problems:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Are times of day",
"related to problems in taking your medicine? What times are not",
"convenient? Did you miss a dose or take it late more than twice during",
"the week? Which doses were most often missed or late?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"some locations interfere with your medicine schedule? How often are you",
"away from home when you need to take your medicine? Does this cause a",
"problem? What locations cause the most problems?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"some activities interfere with your medicine schedule? What activities",
"have been related to missing or being late taking your medicines? Which",
"of these activities occur on a regular basis?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"other people interfere with your medicine schedule? Do you feel",
"embarrassed to take your medicine in front of certain people? Who? Do",
"people tell you that you don't need to take so much medicine? How often",
"do you see these people?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"moods or feelings interfere with your medicine schedule? What moods or",
"feelings cause problems? (For example, does feeling sad or discouraged",
"make you feel like taking your medicine?) How often and when do these",
"feelings occur?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identifying problems in taking medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"3\" rowspan=\"1\">",
"        During the week, did you miss or were you late in taking your medicine because:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        1. You felt good and decided you didn't need your medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        2. You felt good and forgot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        3. You were involved in an activity and forgot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        4. You were interrupted and forgot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        5. There was a planned change in your normal routine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        6. There was some unexpected change in your normal routine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        7. Your medicine caused you to be sick (side effects).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        8. You ran out of medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        9. You felt the medicine may not work as well if you used it too much.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        10. You felt that the medicine wasn't working.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        11. It was inconvenient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        12. You were confused about what medicine you should take.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Look back over your week's records and your answers to the questions above. Use this information to identify the problems you have most often in taking medicine as prescribed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24461=[""].join("\n");
var outline_f23_56_24461=null;
var title_f23_56_24462="Dermatochalasis";
var content_f23_56_24462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatochalasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 112px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCABwAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDuopW2nOT83rVuKNmDMu7AB5zxn0qhCxBbHfjpWhbblTbuxnk1nY9JFoXRS3U4JJXj3qzFeRC380SDbjJ56VjSRzrOI4J8MOSu0ELRd2H2mL97M5JYMy4AVseuKht3LSQXl5JKWkhlC7jhVzgsB/d9frT7G2usiaKFzK3PmOfu+wBNFqn2W4klwPlAADAn5fY9ua6FnRYQZWXAxwAaSG3Yw5pJg6/aGlwp5LHAwfYDpVtJYY4S5lQBT8rhsLn8RzVpYxcyiQI0SHo5PX6U428AlVmdNy/xsBx+PrTRLMG5ihu5jJZwSOi8BgvMh/w+tWreyvQ6tcGUKf4EwMfmMVuomHxANyD+Mk4H4Gn4BycYz046UWKWpTjtEuFUO8yqBgqGGD9cAGp4tKiEYSEGBQMBkbafx9fxq6tsjpukcpx1j+Vj9T3/ABqGOPy3JDZB5zgZNVoiVFspSWThwzskpxjhcH8eeaY0BVgplJP9xun5VswrnJJUE8k56VKbc4+6CD0yKn0L23McIxBU8gjkU0Ky8biw9/StOWzCKAVXOPxFVZLdo24xj65o1Q00yFFKkkEgE5prO+FXPbn25/8A104hlJ/lTCCGJPXvntQFkDgnCgkLnJ96YJMK2G3I3QHgj/61RSS4B6n6VXZggA4z3ouVZEksjDBBJIwGI7jFJc3ZZPJJJDdNvbj/ABqpIxJwByakhjKNu65pbhoaVrE0pSWQ7mBzj2rSVyJVxwMeuayI5Sq8Yx79RV6CQn5hjFLYcddzRjZtoJJ47/jVyAjJ54JPFZ8TGTkk5J5xVyOdIl5Ei8H/AJZsf5CqiTUWhdiyMgDGQME9cVWnmjiidiDjcBgdSc9B7moxfbv9VFNI2OCV2D8z/hUDB5GV5mDPk7EHCp/iff8AlV8yMowd9RsAbzXkmCktubg8An+nb8KJmZTubsnP506YbXwCOFqvO5+UkYJXnmpbNStcygSDaTv5I5qjeyiJEboVwB9BTryTcQT6Y4Fc/ql220ojHJYD1qAtcvy6kvmHZLuZuvOePSoIZC0jkk5b14qpaxZUb8Mx56c1eVBgEdaqxHMlsXIZHzyST7U/ceQ2cZqFFIzzzT87sZ60BccQWbg/hVLUkRo0hVVBkI3YHRRyfzxitEhYoyzAsR0A6tnoKZDabpZCzb3UDcw6bj1x7dBSewXVyOCMsQ5J3Mc5q19kdlwry7ieMHrWlDaoqZb/AICR1FPVCGbeFBGCvPNUl3JbvsYb5gmhADK4DBsn0xVws5TGZNuOTtyfzxSyRyvdmXYcY2gZ6jPJ/E/yqSNZpspG5XjOPpTQnG5m3Mdu6v5kYcgYDyHJHtjgVAumNOjPLI6rkFU34A+qithIQhYyr5so5Usc4/pSK0c7sJFKuByj9R/9albuG2hmRyNbYjdgc9Cg3Y/AciorovJsaRbgQjk/Jgt+XOK6CVo7e2eRwBEOrdMVQ89pRv8AJRF7KSC34+lJq2gkyhbtbtzFK3B5G7OPqKrX7jOSGYf7JKk1PqGHKlYT5obhxxj6n09qrXskzAxxuqP1wRuwPU0D63Od1a6WPcArOeojIy36jj65rO0N3eFt6yOzE4XcQq89K6H7LyzSIjE9955PqeOfpWPeQtBJIWYRow3cHlj0/DtSae5ataxNbKJg8asyxqMHB61Q1exWGHejHDZGM81qIY/KDqyoQvTPSquotHNFt3qxP905q0kYybTOUgvXjjMLOe/JbOSOtZV2zuwIYk7hjmptSdlv/JQRqVHULgn3NOCrJKm5hjPJAqzF6M9LWTfcKq8AHJrQ+05TZbxl2X7xXt9TWdYYaeSTbnk4HrV+1ijSH/RwFGeUHY1LOhIsWYV3X7yZ6jPU/WtLyhghO45Hasu3QPKyOCO4B6VfH38I7Z/uqc//AKqg0EmTbFtZgjDp3J+lXw800Kq7xH2KkfnzVUCNnxMr5xz1b8c063khi3bcuTwuCSfxFCFuWk+0yExRlAj/AMRH+JqeGzeNMiZFOeCUU5/Sm28u9VjAKEn5i5ANaRKyREJ90DqTwBVJD8iirzhyjNE4HcArk/rVxQd3y5LeuelUnlLMEiP4qOnsM1YjaSEnA7ZwzZpXLt2HTEl9u3riplb5iAM561DEW3clc+1TpjzTjg0vMppIkTGzOB1z1qyXLEAAk96hxtQE4BPvSRBlk3EEZ5zTM3Z6kmzdIC5Oe3FRPCs8m1Cdv8R9aSWcSSAA4A/Ol3iNSw+Ygde1FybNEU1ugBVE9gO+ao3NttO0HJ71oxuqKZJc7m5ApiN5kxfgjtkcUbhqjFltJA+xQS5/SonsmTry3r1rcm2+adhznqfX/wCtTTHkg/lTRLkzC+wtySDnvUTwGNuldJ5Pynjgd/SqNzFwc49qbiSpu+pkgtHkFSc9as2Zbb2zUs9s5iziqULFXCkkc9MVnJHRTlc6G1XGDjJrQjzkYOeMYrKtJN2AucCtS2Y8bVJOaIinckXBKnAB9BUNyECg4zgY44q4sMhGQQvPFQywNlTkEE81bvYzjJX3Kb/MoA+V8gc9qzb99m8sCG6j6VpzQOZdpYDqaxLuAgHLHkmodzRNGTqE6x5IYZA7VzsR+0T7wDtXp7mretkQhskk7sAetJpUOIwT1pxV2TOXLG5o20TbauQw5Of0qW1VCgBzV4QKY88cdM9a2cTnjK+5TEYx0P41IYwVwB82KnjRlPBBJ/WnOoycfK4/hx1qGjVFWfMKxSSLmJG3MVydoweSOvf3p1hKpaRlIKPLke+FA/oakLts7bgcVBtizwXQn+6xA/Koa7FpdzWScRx9Rt7gmm3zmS2WYcY+VTjnPQE1mxypC2XIY+5yatNKskZ8pgVbnGe4ouPlsX4oVit9jEhgAQx/iGMD8aicCN1mztLZDHoPelhukkgwRyBgg5+U08rui2HLD7wx1FP0JtbcSULkAgK+MgA5yPaqd8sLorcJODhAASSfTHfPpUgVH/cTt+7zlGJPyn0z2qb7OLN3mhRcOMNg5PPuead7iatoZMaSyNumWRVjPEOc7T6n+lRzblBzjjncetWdVuA6+akjCRRhxGvJ/wDr1mwXBO0mLI6iTeAP/rUrCtpcRDbOn72aRs4GB2+nNQI6x7hsO4npnLNjvUl9DLcTRqoWMDLkpyx7Dr9fSqrpHbBldCT03gnJoER3cxR+V3ZHChv6VjXsG+SMyqJAQxwBwD1rWWSMMV2bG9NuM1QvZfmi3qdgJIOOhxQCdmVnEYj+SNdw9RUFsJJQYxsGCeq1cmSGSMNuOMdUNZbu0Duxk5xxnuKcdCZ6o4nxbG0N55mduDtJHcds03TpA6IG4JxVzxKGnSVmK7ivHFYelSvvAOXYEbqd7ES1PYtOXK5Y5JbpmtC7t4uHDvHIB95D/Md6qWIT5VdcEHFW7i5ie5WNAWxz9fc07aGvUr+TesUb7QzbTlSEC/n61eSW4ijxM6EH+5waktwzDkj6DmqpU37GSPBSB8o3ZmHUf0qGi0+5p2cp6x2zgf3iRz/jWjAhdtxwpPfJzVOxIZPlB9cZrUh2bhntxg+tCKehMN8Q3ZDY9RzSNI7hVGGJ6r0p08ioowwyPSqjvmLzcjODg56U2OK6ss2jKtuWI4YbvqalhDP8+3g9qqQjEaxscYGcdv8A9dXVc7VGQnGP8+lFim7CBzkJGOTwSeKlUJH1YEkdQaxdW1vStJjLandRw9wCeT9BXK33xA01tD1C/sCH+yMq+TJlHfd/EPYUKLexE60IL3nY9CmuYtqgnJz07AVQ1LV13CNW2sRkAda8OPxI1fVotlt5VgpJyUHmSN6Y9KSxm1qWfzop9RmkZtzFzjP59Pyp8smSqsL7NnuVrckx+nqaf9qVjtVt2ewX+Vef6NeavBAg1BRKTwWHBFdJaakFwBuX14qeU0l3OgUvK+ZiY41Hfr9MVPJMjALEuBjGWNYwvBIcqwJ+vFWIpx0BBPUk0vQVm9zQUZyF+6OretTRnOSTVSJywDMBt9PWrcIJU/KS57Y4WqiZzViYgbQuck/pVK5UKwHU1ejRuSx4HHFUnYF93vWj2MY6sZJ8yYrIIKznjPrWxJjbyOtZ20mcbRnmsJHRTNOwYbQeNorVtyFUbT2JrPgVVC5Xkg/hVhtnl4IOM8Y4pxdhyXMXwpYElsjr6c0w4BIKk88H/GmAbkUJjHQUDeinvjqBVmNitMrJIzDaKxb6JiuS+ODwOxrZl3FSSeG4FZF4FMLg9QfWoZocHq0QN6oBzjJJJq9ZD5B6VW1eMC8RsHrzVoHyyMHgiiDsOor2Oi0sRspz0FXJNnITj8axNPuWjcqDgda2oWzhiRgjsOtbXujFQsyJ2x1TAHcGo2nUIQ3zHtuHT6GrzCJo/l3FuflNZsyxFWPCMB8uSTn2qGbxtbUq3E64++VP1rMudTEP8St9RzU11E8oVcKvcAdfxqrFp7xyrKD+8Ughs4KmoszS6SK02o3MjACDAz/FwfyrNvvEUmmKZBKnBwUzxUuurcwJssvNa4fsMYHuTXN32k+V5DLZTOwJLuzb2YnvjNaQjFuzMqkqkY3irnV+HvHNjf584taXA4xICFceoNdPYeJbGa4WOO5i+0DgKG+9/jXkF28aMd52L/dkUqf1q5Z+I7TSvDeqRT6NHdi6ZYlvhyYGxkKDj2zwRVuilszj+ty2lE9tnljnXd/EeuPWpUnKReVIOR0cc8elfP3h/wAf6na3ZRp/tVnkAiTll+hr07RPF1lqqgeascg5wxHP41lZ7nQpxkrXOjvECSEMpBB44xxWdJCYyXSRMMTuRx8p/wADVo3kdwpKOp57HOKaJvLZtuTE3XjNBd9LGa4kEuIYmXC9GbKjnt3qOW0fJYlDJ6EfKKsXjvFNE6jcrZBB7d6jeR24wBHj5iOfypEtMzJzJGuTEMf3lG4f41VmlMzBfLOV5+XvWnczHZtiVSMYzkfyrGn3K7lH3OOcDjFAt0QSZUsAhDe/FZF5NtidnGcgjBGDWlc3rggtGQ/sc5rP2+ZKs9wfLxwEJ6D3p2Jb7mFrUSvZM0o+bZwQK5/SF3tEEXLOwyO9dlfwsYHWPDIMjg9K5gQNptuJHfF5NnYo/hT+8fr2p2M27nqMieQBjzGdmwo3d/f2q9Z2yp88jFm6tuP9KZHGvlPcSHccHO7oAO1Q6conzN+88gjkk43ewpG/QuR3Im3xKGRTx5mcDHetOxhVVVY1wgGAMYA+grOgiEk++QDA4VB0UdhWvHIAQqDLDoPT6mgaJ1Ty2LLt2HqCOlXIGCEEAMByT0qJMiPnO4n04qKYRoG2ggnsCQDQikrhqUjyoPLYBi3TParMQxAvmqpPG0E9D6+9V4YyQpA4T+H61U1jUjZKI4QJLmX7ik5x7n2pdbml76Iu3mo2+nQia5lEXzYy3c+wrltV1u/1RWh04/ZIGO3zf4z9PSpYtOaeWO4v5Wml5PzdAfYdq04bSF2bMXA5PHWrUH1Icl0PPv8AhBrW4kMs7XFxMSQWaYkk/nWzZ+GLK0s5oIUxBOB5qbiVkK8jcDwSOetd3YxRwSJIYlfHUeoPvT7hI0uJDp+RuwG3DIPfv0P86rbYz+J6o5qw8NwI6x2tvGOMnCgcVsWuiKrR4eNRJyCcnH1rRsleLAMwAUEYVecHqKVyFXsFXOAM4pbbml29Ct9jiCtkqsi9Mcgn0qMxo24rlXYYJU4yPQ+1LtLuT5ny9cU5gwBEIJAGWOM/jU3SLcdB1rpdubdpEcm43gGLbxt9QfWtzT7S2a0JjCideWz3X2rPtkeEAuypKrBgAThh+HFWI5WSUyIfJkLM3A+X1AH8qLpbGDjJ9S9BCvUOzHoPb8KGOz7v6cVJHcvMoaaI7yuRsHDDGe1NieKc7Yz84GWB4o9AXmQvNJ5W0EBfb/GqJ5kAA6VouFDZ3LgfjWcpy7Gk2+pVktglYhSfSq9qCXLDr15p9y/ye/8AOi3OyIE9e1R1KWxqWhdQMgHj681YVS7pgjINVrfcRweOw9KtxZLD7uAPzq0TLQkPmYIILDGMVEcqMqAM+nNSyY2nAXOeKhZ2244H0FUyYleTcFwrYYcjisPUXDOQp569K2LiYhsnBwOa5q+nCz9QP61mzeMWzI1WPe+cDg44qFRuhA7irc/zIemT2NVkGM5HGKRMiSFjnk4x3re0u43xhJQSQeOelc7CpZ8Z6HFb2lR8HZknPbvVKVmXypxNkxAxsfNVRjp/F+FZ7xBQGl3sM8lew9q1InaNORzjgVQvrkSsUyOmCOmPehz7Exj0Mx5FiEzRp5nB2jof1p0DO0Uco3RuexOVJ+mOwNSRny2YhAwHXPFTPKsqhREVVSDjf+f504y7lumr7FZLEONxCs54wBk4o/s1Zbd5YwuxF3HHJ9OR2/Gr6nDPKk8CSkkLHuIK+4IpLXdbwXAWFLvfhizEjA+ncdaqwnJ20MK60NLjzFKR7UGWDY571n3PhuDawSFJYwokBVeCp6ECurhi23RSCKHEvV5ACpYc9+nXtiqVwLi4lmEMReVmJLsufrjsBn0ppaE3k35HCz+HNMbLG1h27tpOwDB9DWZfeGrWPdsgjwMD5Bwe/Ud67rUbXz2BaKNNq7HCjAb3+vvWf5Plq6FjuzkMRyDRcOVnFQyX2jkvp7GNXYFlOWBAHf2967nRNZjvoAScSD76t6+3tVGaMOoJPzDjGOKqRWT27bkwoZiSOwqXHUbi7anaSDzVyFJA6D0qrG2xQjEBScD1FUNJ1J0/cXDbh2c9vatS4VG2l8ZJApNGL7MglVC7I2Cw6EjqKxLy0t3BZol3D+JflNaV6MHeruHB4J5qkvmyA4KlQeTjFF+grdTIaFEx+7Zj2OQaqNAHLj5Qo+8C1a1yiq5+Q789c1RuLVGJGOccENTREjMYxW8h2LmPblkz1rnLwJLdLLKzCSR8yZ7eg+ldDLbEEx/PIvcjqBVS7sIG4AJ6EDPOaZFlc7u9EUkbK4ZlfjYmfnGadAk5LGZFRQMKgP3RU0EXln523t3Y1dWIOCZOf5VLNVoRW0DSBWaQ7BwcDn860rONYk2gDnn61UaMxuvGB14q4WwqnPsaRRds5AHOeg/GoJcTPkHkHqO9Qwk5JBOfr1qO5vFtg2PmY9FHU0XKS10Ev7w2cQSMhp34RR/M+1VrCwAfzZnMkrdWY5NQWdvLcXLXM4O9uAP7o9K3oItq/N1pxaWrKlfZDvIUIp4KmpbaNQGYFc+hNSRodpwM5GCBUqRj+6R9apzBQshI0Ypnb8gOCRUqQyKCEAxjOARg/wCNSwxD+Hn271ZWL68DrilzCaSKLJdBFUjchGVxxioJYWRDuYl9wAOPu+4rXI5yWyPxqrKg/h49RUuXYqNjN+zqrZfOOCMDj61af7qbAq8bTt7j3o2KGUgnHQ/WrAVSR1GOhHHNSm2W+5AsRjUFV4PrUmHU5IAYHI46GnMco/PHsMfjUY3MAqnGecGmkTcbEXVt7DaBkg57/SrPEcWUdCXJOEbJAHrUTGNVCEHdjPBzVNjulbPA6YA/zmqatqJ+8XJJhjKnk+o6VURs59aikfZnPbgVJagsOTk1m2DQXB2pwRmmxON6DOQPWob99uBz71DE+3BOdxIwKEzSELo6GCUbuFOMYwKsxysSAqhR696zLNzgAHk81oQgZ5GTWiZnOKRZYkjLMc1WkwR1UehFTDODySPrUE5GBjFJmcdChfEpHhueMZFclrBEQLg52kHj0rqrtuG4IzxWBqMO87QAQwxk1DOulK25QeUfIxA2OO5psZUlepyOtVljeHfby/eQ7oz6jv8Al/Wrdku9Tk85zT6EVEkh4jx8w4DdfqKlsr2S3lcHIVxtxU4j3I2Kp3iFiGA4JBND1MoOzszoozLGkbqN4YDnPenTocbmIwR90isjT7t43WJ2O08c1s22zBwc47HmtUk0PmcWU5LNdoZWY8/QUyJST8y5UHGP8a0Zk2xtlc/wgnr+FRBDtKL90MM8dazaNozutStJhlVVVAOue/0pfnwAQccZy2aeIXy5Kjb7dPwpoVwcYwKizKLdqfLAfywh5AfOevpSOyQKArhXOWUr2zVaJc5Az+FEkIByOfr1rSMtDJx11KssSu5bP1qtNBHkjrkYq4RtXHce1QtGCSSPyqkxO6Mh7XcdqjjPXFOezJTb2rUVAvTrQ6nHIzQHMzFeyOzApFMsPyyuSnWtUABhnofSs68hkbnOaVyLNslBWSPcfmVuQDUK/Ju+UlD6VkzzT2pVY/XIHY1Ztb3zcK6hJDyBmhO+xnODS1ILtZGfCoxXt64qszFeZAQw46VrMjynBG3vSR2mCzPy1OxlzLYyCqRIZFP3uorMuWjkCSnaJAcYPet29jwpJGfb1rm5yFnAzujJzz2NO4krnoSYdzwM5wKvwoAqgjvms6IgPnOMHtV9Z1CDJ6VFzQuNAJu2CB2qvJEVQ7XXjsarvqcaNhWy3TANAM1y2W+UH86LopRl1ITLMzbVXLnstPgsWD+bKf3hH5Vp2tsIxkDmptm5uBSsVzdCG3TAx2q2FIA28j0p0cVTQqS2GpNMpNDrcr+JrQWMYGSPzqFYoj0yMd+9SMjKmUAI96pJrcbaZIiL26ip1ORjH51Fb/MvPHfGKsgcENwSatIxk9SvKSOBVeRAScg/X0q7KgBJHPbFV5O2RSkioMprGDuyeKeV6Y9fWnOpR8+gGRTplZcKARnBzioSNWyBBuVd3Qmm+XiZQDjIG3B74qVo8BQelErKFIAGTxnuBVIhvXQhuNsSEMVMh6kc1nhwrLt5wckVNcnJOTz9KihXLDnmolK5cY6ajZA0koB455q0vyICOM9xTFX5yQOlLu4ZzkhRgD3PSoQ7GXeyBpgBjGfzp0IPmL7dapXjYuypJ+XjPpWjZgKqsT8x5xTubpWRqWgIycfQVbjwOuR+NVYm+X5Bu9ulXYipXGDn0qlqYzFDbjw2R6UgUHgf/rpxxngHB70jAr93mmZlG7hUAn8MVh3QIYRyLwMkMK35+meCRWHqTKBlPlcHqKlmkLmJcxPdRiSFgZoWLCM8FvUA0mmSo5DoTtftVae4ktrtJF5Vmy3+NLZyqL+5MXzIXEuR0yw5H5/zp3G10OjjQ7QwzgjP1qrcKFdxg4cZB9DWnaKOEOfLYbgcc5//AF1HLDlWOOnSlexlYzNhDZPXr0rXsJFC4LFSevFU5ojtDLyRTBv2gg47ZqlLqgtfRm+mHkcIx2AYwev1FMeMbsr/AKssQR3FR6ZcAErLzkY61ZibcGXGAWz+FXuCdmOtolXaJQdpU49jVcR7Xfuu7gkVccueGGAoB+tSpjIYIBtPPGetHKPm6meISGOOD7cUyQGP7y8Hnnitfy1OC2cjg4GaSWEvEE29RwQcYquUXtO5i3KBkBC8+oFUShJwwNbDxYG1xnFQm3ZSQxG09DjNTYtSVjMZQvJFLwwqzcxMFBwCO+Kg2EDp0osS2QtEM7hyKWGGN3PmsoXB5IzzTgRg9qhZ/nwKVrEO5i31mwu4tzo8akncuaiuNOiBypI7g+lac69snP8AKqE7FG2k9ueaEkkTKUmDNPaYXBnQd1GDVOTVFJ4Vhjrx2qy96iqMKfMB+8DxiqLLvAYDlmzj0FUzC2uqIbm5Dbhnr1z2rn9TZTNGEJGWAx610N9CtyhC/K4/i71mLYiXIPDpgj6ikxo7kWhMn3iB64pWtlUbRl3PYVbaJ84ywP8AKrNvAFbcqnJHJb1qTUxktRFLkpgmtKBhkYHFSXEfzZwc1EitngEfhU7Gm6L6NkH2pVOFJFRJv285NWUj3YAFUiHoOjLNznHFPtj843nA7mpUhCjPNSCME9we+aHG41JFqHGB0/Gpwm4ZT/61QRDAAIJFWAygDaCDVpENj41Gcu35cUO+1jtGT703f/eUGopJ8scfTpT0QkrsdIQBkjntULckdc05nJ45wOmaaMryRyalmi0GkGTORg/4UrsWY7znAzSLzg4/Omhe5Jy38qhljXYgEnP+FV3yWyxz/Src3zfLyR3z61AyEADHFTJ9Co2KcgVj6mki4PTA9alYAE7R+lK0RJHykVBoPC4QsoBPQVW1E/ZyvIOzB2+/WriqUUNzgcciqOqKPsD7hkjoCOnvVLYmO5hKfNuVaQEhnyfetyARswKEYz6dqw4ldwZmAUKQVX3zWzp4/dAc8dgKZqzVhjYgcACrEcYxgnn2pYAcAEdqnIGCc4NUkc0pjUXA2kn1601gD09KRiRjccimu7EjbjHr0NMkzZSVd0bjuMc5rGvRvDDj3rcu87Tg/P61iXZkXdlT+HeoaN4yuYNyuJgCoIHGD3rNtGNtclAMIx5HtW3cwlgCMgjmsq7gdZchT1znFJ7FXTO409kkiiU/KwHX0P8AhVuSHhipwejof51iaNI89sNqDcoGcenTNdEFJgR/vFTtII5qlqYS0ZkzKY8gqetQYG0gVfvUKpuI3EVRCMRnbgnrU7BbS4kYZWJB5HNallLnORnJB5qiMgjrgdsVbQFDviyRj07VcdCW7mgyOwbAJXpTkBXKkZ5qO3k+QrggH0/SpiwUqxzyMMOn0rS5N+g+PcN2Ad4/WpYZFKHP1HHH0qo0jedujXPrgU+Bv3rY5Xrj0pqQpLQluIw67lB64I/lUMiKuADuXGcZqa4IQAA5GOcdqpyPkbQCQKbZMble7VSPl6D1NZrA7sEfSr0qvtJ6ioWyRkg0tzXZFCYYz2qsVw2SM5q9OCw7j8KqEEhxg5HtUsL6FecYGRnPrVC7RGBbADVpsreUMAsfSqlxEWGQG96LEXMKZCVAyBkHBqfTkIbLHJ9DTpIt0m1kb2xUsKPE4fYfcYpAwvrZdgkTGfSqUS4k2sBk8A1qSkkYUHnsRVdoWyMpg56UPyI6an//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Redundant skin overflows past the upper eyelid margin. The clinician must lift the excess skin in order to find the eyelid margin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24462=[""].join("\n");
var outline_f23_56_24462=null;
var title_f23_56_24463="Ulnar nerve test";
var content_f23_56_24463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulnar nerve test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The examiner attempts to remove a piece of paper being held between the patient's fingers. This method tests the motor function of the lumbrical muscles that are innervated by the ulnar nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_56_24463=[""].join("\n");
var outline_f23_56_24463=null;
